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Esterases/Lipases are evolutionarily related enzymes mostly belonging to 
hydrolases superfamily sharing a common α/β-hydrolase protein fold. Recent 
studies have suggested that they play a pivotal role in disease manifestation due to 
disruption of lipid metabolizing enzymes and their pathways, yet only very few 
have been functionally annotated.  
 
This study focuses on Mycobacterial lipolytic/non-lipolytic enzymes comprising 
of 31 putative lipases and/or esterases belonging to α/β-hydrolase fold family. In 
silico molecular modeling, sequence analysis and ligand docking experiments 
provide insights into molecular structure of these classes of enzymes. We 
performed a unique structure based virtual ligand screening to predict natural 
substrates of 4 putative Mycobacterial esterases/lipases namely BCG_1460c (lipH 
probable lipase), BCG_2991c (lipN probable lipase/esterase), BCG_2950 (tesA 




The information obtained from molecular docking and molecular dynamics (MD) 
simulations was preceded with an in vitro study, where we performed enzymatic 
assays with whole cell lysates of Mycobacterium bovis BCG over-expressing 
lipases and/or esterases using synthetic substrates. We provide evidence at 
structural and biochemical level that the short-chain esterase activity of 
BCG_1460c (lipH probable lipase) is inhibited by tetrahydrolipstatin (THL) an 
FDA approved drug. Overall, the in silico and in vitro analysis show high 
correlation and provide an effective approach to characterize and distinguish 
mycobacterial lipolytic/non-lipolytic enzymes. 
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1. Introduction  
1.1. Esterases/Lipases 
The biological relevance and coexisting variability of lipids has led to the 
development of wide range of lipid metabolizing enzymes. Esterases (EC 3.1) 
are widely distributed amongst bacteria, fungi, plants and animals defined by 
their ability to catalyse the formation and cleavage of ester bonds. They are 
classified based on the nature of the ester bonds (carboxyl ester, thio ester, 
phosphomonoester, etc.) they catalyse. Among them, carboxyl ester 
hydrolases (EC 3.1.1) are enzymes that catalyses ester bond hydrolysis of 
carboxylic esters (Figure 1.1a). Lipases/TAG lipases (EC 3.1.1.3) are lipolytic 
enzymes which constitute a special sub-class of carboxyl ester hydrolases (EC 
3.1.1) (Ali, Verger et al. 2012) capable of releasing long-chain fatty acids from 





Triacylglycerol Water Fatty Acid 
TAG Lipase 
Carboxyl ester                                                                                                                                  
hydrolase 
Glycerol 
Carboxylic ester Water Carboxylic acid Alcohol 
Figure 1.1: (a) Hydrolysis of a carboxylic ester catalysed by carboxyl esterase 
enzyme. (b) Hydrolysis of a triacylglycerol substrate catalysed by TAG 






1.1.1 Esterases/Lipases in Infectious Diseases 
Several studies on lipid metabolism have been undertaken and the outcome of 
these studies has opened up new ways and avenues to analyse and characterize 
a host of diseases as well as providing newer insights and approaches into the 
mechanisms involved when cells start functioning abnormally and hence 
enable establishing of an important link between lipid metabolism and the 
disease. The concept and hypothesis was further extended to infectious 
diseases which are known to be accompanied by an altered host lipid 
metabolism via a unique sequence i.e. the disruption of lipid metabolizing 
enzymes (esterases/lipases) and their pathways and there also exists a close 
and significant inter-relationship between lipid metabolism and host responses 
to infection. 
It is indeed important to explain the mechanism and the factors by which the 
lipid metabolism is regulated. The frontline and exclusive studies have shown 
that the lipid metabolism is regulated by lipid metabolizing enzymes 
(esterases/lipases) which are considered to be one of the known virulence 
factors in many bacteria such as Pseudomonas cepacia, Staphylococcus 
aureus (Lonon, Woods et al. 1988 and Rollof, Braconier et al. 1988) and 
fungal species like Candida albicans, Fusarium gramearium. Further insight 
reveals that the lipid metabolizing enzymes of Propionibacterium acnes and 
Staphylococcus epidermis are probably involved in incidence of commonly 
prevalent human skin infections where they help triggering colonization and 




Table 1.1: Effects of infectious pathogens on host lipid metabolism 
(Source: (Beisel and Fiser 1970)) 
 
According to some hypothesis it has been suggested that these enzymes may 
also be responsible in contributing to the invasiveness and proliferation by 
inducing the destruction of the host tissues thereby supplying hydrolysed 
material as nutrient to the microorganisms. Lipid precursors needed for the 
replication of the invading pathogens (bacteria, viruses and protozoans) are 
derived and supplied from the source metabolic pools within the host by lipid 
 
EFFECTS OF INFECTION ON LIPID METABOLISM OF HOST 
 
Presence of invading microorganism  
 
 
Secondary effects due to infection 
1. Direct Effects 
 
 Decreased dietary intake of 
fats.  Utilization of host lipids required 
by replicating microorganisms. 
 
 Disruption of host cell metabolism 
by intracellular microorganisms. 
 
 Minimal interference with 
intestinal absorption of fats. 
 
 Localized destruction of fat cells at 
sites of an infectious process. 
 
 Altered lipid metabolism 
within host cells. 
2. Indirect Effects 
 
 Altered rates of hormone-
mediated lipolysis within fat 
depots to supply increased 
metabolic demands. 
 Alterations in host lipid metabolism 
caused by bacterial exotoxins, 
endotoxins or enzymes. 
 Activation of lipase and other 
lysosomal enzymes within host 
phagocytes. 
 
 Altered rates of lipid 
synthesis within the liver 
 
 Release of mediator substances 
from host cells, that is, endogenous 
pyrogen, interferon. 
 
 Altered rates of fat 




metabolizing enzymes thereby altering the host lipid metabolism. In the 
subsequent process of progression and infection may allow for the re-
distribution of nutrients to cells which are considered extremely important in 
ensuring host defence or tissue repair.  
It has now been well established and recognized that certain pathogens have 
the inherent capabilities to co-opt the lipid metabolism and some illustrative 
examples can be listed as: 
a.) The ability of Mycobacterium tuberculosis to catabolize cholesterol 
as an energy source which might as a result facilitate and regulate 
its ability to survive within the macrophages. 
b.) Utilization of host cholesterol by Toxoplasma gondii for its 
persistence, growth and proliferation. 
c.) Heliobacter pylori being unable to synthesize cholesterol and 
hence requires exogenous cholesterol from the host. 
d.) Ebola virus (EBOV) in lysosomal compartments binds to 
cholesterol transporter protein Niemann-Pick C1 (NPC1). 
Fatty metamorphosis of cells particularly from liver, kidney and heart is a 
common histologic finding during a host of bacterial infectious diseases. An 
increase in esterified fatty acids has been observed in viral hepatitis whereas 
free fatty acids and triacylglycerol (TAGs) have been reported to be elevated 
in gram-negative bacillus infections in humans. Since the action of hormone-
sensitive lipase in adipose tissue is a major event contributing to free fatty 
acids to blood, such infection-related hormonal responses may have a pivotal 
role to play in altering/affecting the rates of lipolysis or fatty acid utilization. 
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1.1.2 Biology of Mycobacteria  
It has now been reported that the genus Mycobacterium is known to comprise 
of more than 100 species (Tortoli 2006). The cultivable (grown in lab) 
members of Mycobacterium are clinically grouped either as the Mtb complex 
or the non-tuberculous mycobacteria. The M. leprae, which is responsible for 
causing leprosy is an obligate parasite and therefore not cultivable in vitro 
(van Beers, de Wit et al. 1996). On the other hand, diseases caused by 
members of Mtb complex include M. tuberculosis, M. bovis, M. microti, M. 
africanum and M. Canettii subspecies they are known to possess and 
demonstrate very similar clinical features. Pulmonary diseases caused by M. 
tuberculosis and M. bovis are clinically, radiologically and pathologically 
indistinguishable. However, M. bovis appears to have a diminished propensity 
and potentiality to reactivate and spread from person to person (O'Reilly and 
Daborn 1995) through human chain. Calmette and Guérin (BCG) attenuated a 
strain of M. bovis to generate BCG which is used as a vaccine by continuous 
passaging through culture media. Mycobacteria are aerobic and non-motile rod 
(bacillus) shaped that are identified to be weakly Gram-positive and acid-fast 
by Ziehl-Neelsen staining. The bacilli belong to the actinobacterium family 
and all Mycobacterium species are known to share a characteristic cell wall 
architecture which is relatively much thicker than other bacteria and are 
known to be hydrophobic, rich in mycolic acids. In the laboratory, Mtb can be 
grown, in vitro, on the agar-based Middlebrook medium or the egg based 
Lowenstein-Jensen medium (Parrish, Dick et al. 1998). Considering that it is a 
relatively slow growing bacteria, it takes a time period of around 4-6 weeks to 
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have visual bacterial colonies formed on these solid media (Parrish, Dick et al. 
1998).  
1.1.3 Mycobacterial Esterases/Lipases 
In Mycobacterium such as Mycobacterium tuberculosis lipids play a vital role 
wherein it is stated that a large fraction of the genome encodes putative 
enzymes said to be involved in lipid metabolism (Cole, Brosch et al. 
1998). Indeed, Mycobacterium tuberculosis genome contains 250 genes 
encoding putative enzymes involved in the synthesis or degradation of lipids 
compared to 50 genes in Escherichia coli, which is known to have a similar 
genome size. This feature, combined with the extremely large quantum of 
lipids representing 30–40% of the dry weight of M. tuberculosis tends to 
suggest that lipids and lipid metabolizing enzymes play an important role in 
the mycobacterial life cycle and perhaps also in virulence. In the study 
conducted by (Deb, Daniel et al. 2006) group reported the expression status of 
all the twenty-four putative lipase/esterase genes of lipase gene family of M. 
tuberculosis H37Rv in Escherichia coli BL21.  
In silico analysis has identified the presence of around 31 putative genes 
encoding lipid metabolizing enzymes (enzymes involved in lipids degradation) 
including 24 lipid/ester hydrolases belonging to the so called “Lip family” 
(LipC to LipZ). These have been annotated as putative esterases or lipases 
based on the presence of the consensus sequence GXSXG which is considered 
to be the characteristic feature of the α/β hydrolase-fold family members 
(Ollis, Cheah et al. 1992). The functional classification of Mycobacterium 




Figure1.2: Functional classifcation of Mycobacterium tuberculosis genome                    
(Source: data from (Camus, Pryor et al. 2002)) 
 
1.1.4 Role of Esterases/Lipases in Mycobacterial Infection Cycle 
There are a large number of mycobacterial species such as 
M. tuberculosis (Garton, Christensen et al. 2002), (Schue, Maurin et al. 2010),  
(Peyron, Vaubourgeix et al. 2008), (Daniel, Deb et al. 2004), (Deb, Daniel et 
al. 2006), (McKinney, Bentrup et al. 2000), Mycobacterium bovis BCG (Low, 
Rao et al. 2009 and Low, Shui et al. 2010), Mycobacterium leprae (Mattos, 
D'Avila et al. 2010) and Mycobacterium smegmatis (Garton, Christensen et al. 
2002 and Dhouib, Ducret et al. 2011) which predominantly demonstrate the 
accumulation of lipids derived from host cells. In addition, the consumption 
pathways involving lipid metabolizing enzymes (esterases/lipases) have also 
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been identified and expressed. In particular, the tubercule bacilli enter the 
body by inhalation of aerosol route and reach the lungs where they are 
phagocytosed by the frontline pulmonary alveolar macrophages. 
Subsequently, host response ensues which consists of recruitment of 
lymphocytes, macrophages and dendritic cells leading to the formation of a 
highly organised structure termed as ‘granuloma’ a major histopathological 
hallmark of tuberculosis (Singh, et al. 2010). In these granuloma macrophages 
containing bacilli accumulates intra-cytoplasmic lipid inclusion bodies (LB) 
which are predominantly composed of neutral lipids surrounded by a 
phospholipid layer that reveals and assigns the macrophage their foamy 
appearance within the foamy macrophage, phagocytised bacteria preferentially 
metabolize lipids rather than carbohydrates (Wheeler and Ratledge 1988), a 
view point  that is supported by an evidence showing up-regulation of several 
mycobacteria genes involved in lipid metabolism (McKinney, Honer zu 
Bentrup et al. 2000). At this stage of progression, the intra phagosomal 
bacteria acquire and accumulate intra cytoplasmic lipid inclusion (ILIs) in 
their cytoplasm (Figure 1.4(B) and 1.4(C)) and persist in a non-replicating 
state ultimately and eventually leading to dormancy i.e. latent infection. It has 
been demonstrated in an in vitro model of human granulomas (Peyron, 
Vaubourgeix et al. 2008) that these lipid bodies (LB and ILIs) serve as sources 
of carbon and energy for dormant bacilli. The infection cycle of 




Figure 1.3: Mycobacterium tuberculosis infection cycle 
     (Russell 2007)                                                            
 
within granulomas and as a consequence aiding in reactivation that can 
ultimately lead to an active tuberculosis infection (Parrish, Dick et al. 1998). 
The typical foamy macrophages having lipid bodies, LB surrounded by Mtb 
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bacilli and intracytoplasmic lipid within M. tuberculosis bacilli have been 
shown in fig 1.4  
 
                                                                                                                        
Figure 1.4: (A) Typical foamy macrophage having lipid bodies (LBs) and 
M. tuberculosis containing phagosomes: arrows depict phagosomal membrane 
around bacterium. (B) LB surrounded by several M. tuberculosis bacilli 
intracytoplasmic lipid (ILIs) (C) Enlarged view of (B) showing large 
intracytoplasmic lipid within M. tuberculosis bacilli  [Adapted from (Peyron, 
Vaubourgeix et al. 2008)] 
 
In addition to attention drawn on the foamy macrophages, ILI accumulation 
has also been reported in M. tuberculosis infected adipocytes as well as in 
Mycobacterium leprae infected macrophages and Schwann cells (Mattos, Lara 
et al. 2011). Further biochemical analysis and associated experimentation has 
revealed that M. tuberculosis lipid inclusion bodies mainly comprise of 
triacylglycerol (TAGs). These TAGs are derived from free fatty acids that may 
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be imported from host or result from denovo synthesis (Daniel, Maamar et al. 
2011). The pattern indicated that Triacylglycerol (TAGs) accumulate during 
mycobacterial growth and the amount of intracellular TAGs peak in the late 
exponential growth phase (Kremer, de Chastellier et al. 2005) and non-
replicating phase (Daniel, Deb et al. 2004). 
Further it has also been shown that the expression of M. tuberculosis specific 
lipase gene family is significantly elevated during dormancy (Deb, Daniel et 
al. 2006) and that in the re-activated bacilli, a reduction in triacylglycerol 
(TAG) levels coincides with an increase triacylglycerol (TAG) lipase activity 
(Low, Rao et al. 2009). Thus lipid metabolizing enzymes (esterases/lipases) 
appear to play an important central role and associate with important 
physiological functions and also contribute to the extraordinary capacity of 
survival of M. tuberculosis within the infected host. These enzymes are 
peculiar molecules that provide a metabolic turnover of lipids and can be 
defined as essential biocatalysts for the hydrolysis of esters containing long 
chainfattyacids. 
 
1.2. Esterases/Lipases in physiopathology and disease progression 
Pathogenic bacteria have been known to follow a number of mechanisms and 
pathways to cause and allow subsequent persistence of diseases in human 
hosts. The molecular strategies used by the bacteria to interact with the host 
can be unique and characteristic to specific pathogens, and follow conserved 
pattern across several different species. Hydrolytic enzymes like 
esterases/lipases contribute to invasiveness and proliferation by causing 
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destruction of the host tissue thereby supplying hydrolysed material to the 
organisms as nutrients. These esterases/lipases are one of the known and 
critical virulence factors in a host of bacterial species such as Pseudomonas 
cepacia, Staphylococcus aureus (Lonon, Woods et al. 1988, Rollof, Braconier 
et al. 1988) and also in fungal species like Alternaria brassicicola, Candida 
albicans and Fusarium graminearum (Berto, Commenil et al. 1999). M. 
tuberculosis is a bacterial pathogen that can persist in for decades in an 
infected patient in dormant state without causing symptoms or disease with 
clinically evident features. In fact, prior to entering into dormancy, it has been 
hypothesized that the bacteria accumulate lipids originating from the host cell 
membrane degradation as precursors and re-synthesize complex lipid 
molecules. Fluorescence studies (Garton, Christensen et al. 2002) have shown 
that large amounts of intracellular lipids forming inclusion bodies can be 
detected in the cytoplasm (Anuchin, Mulyukin et al. 2009) supporting the 
view that bacteria tends to accumulate lipids. The presence of lipid inclusions 
confers and indirectly correlates the existence of lipid metabolizing 
esterases/lipases. During the re-activation phase of the bacteria, these stored 
lipids are hydrolysed and the infection process acquires further impetus to 
demonstrate its detectable occurrence (Cotes, Bakala et al. 2008). What is 
interesting to mention here is that a critical link between storage-lipid 
accumulation and development of phenotypic drug resistance in M. 
tuberculosis has also been established and the findings of several studies on 
non-mycobacterial pathogens suggested the involvement of lipid metabolizing 
enzymes in pathogenicity. 
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In pathogenic bacteria, for example it has been shown that Mycobacterium 
tuberculosis Rv3097c (lipY) is able to hydrolyse long-chain triacylglycerol 
(TAG). The role of esterase Rv3487c (lipF) has been implicated in 
pathogenesis (Zhang, Wang et al. 2005). In addition, Rv0220 (lipC) has been 
reported to be an immunogenic cell-surface esterase actively involved in 
modulation of the host immune response (Shen, Singh et al. 2012). This entity 
Rv0220 (lipC) is also known to be capable of stimulating pro-inflammatory 
cytokines and chemokines in macrophages as well as to pulmonary epithelium 
cells (Shen, Singh et al. 2012). It is also important to mention that the lipase 
Rv0183 has been identified as a monoglyceride lipase involved in degradation 
of host cell lipids and may strongly induce immune responses of the host (Xu, 
Jia et al. 2010). Based on these facts, it can therefore be categorically stated 
that lipid metabolizing enzymes (esterases/lipases) are involved throughout the 
life-cycle of the pathogen and they assume important physiological role during 
dormancy and reactivation i.e. during the course of entire infection process. 
The released fatty acids by these enzymes are then taken up by intracellular 
mycobacteria and stored in the form of triacylglycerol (TAGs) to be 
subsequently used as sources of carbon during the persistence stage. 
Conversely, intracellular triacylglycerol hydrolases maybe required for 
assimilation of intra-cytoplasmic lipid inclusions to exit dormancy. 
1.3 Esterases/Lipases Enzyme Classification System 
1.3.1 Hydrolases (EC 3.) 
Are group of enzymes which catalyse the hydrolysis of a chemical bond.  In 




X–Y + H2O → X–OH + Y–H 
In the enzyme classification (EC) number system, they have been classified 
as EC 3. Hydrolases can be further classified into several subclasses based 
upon the bonds they act upon, for example, ester hydrolases, peptidases, 
amidases etc. 
1.3.2 Carboxyl ester hydrolases (EC 3.1.1) 
This group of enzymes act on ester substrates mainly derived from the 
condensation reaction of a carboxylic acid and an alcohol. Members of this 
group have been classified chronologically based on their known substrate 
specificity (fig.1.5) into two major classes: carboxyl esterases (EC 3.1.1.1) and 




            (from previous page) Figure 1.5: Esterases’ classification based on 
1 : Physico-chemical; 2 : chemical   criteria (L means lipolytic those 
enzymes capable of acting on lipid while NL: non-lipolytic those 
enzymes which do not act on lipids ) (EC is the enzyme classifier ) 
[Source: adapted from (Ali, Verger et al. 2012)] 
  
1.3.3 Carboxyl esterases (EC 3.1.1.1) 
This group of enzymes shows diverse substrate specificity and catalyse the 
hydrolysis of ester bond of acyl chain esters forming a carboxylic acid and an 
alcohol. 
                           RCOOR    +      H2O    →       R–COOH      +    R–OH 
 
Most members of this group are hydrolases especially those involved in the 
hydrolytic cleavage of carboxylic ester bonds are found to share a common 
alpha/beta (α/β) hydrolase folding pattern. Enzymatic assays using 
chromogenic substrates such as acyl esters of p-nitrophenol (pNP) allow for 
the spectroscopic and calorimetric determination of esterase activity.  
1.3.4 Triacylglycerol (TAG) Lipases (EC 3.1.1.3) 
They constitute a special class of carboxyl esterases (Ali, Verger et al. 2012) 
capable of releasing long-chain fatty acids from natural water-insoluble esters 
(lipids) as depicted below:  
 
Triacylglycerol  Water  Glycerol  
Carboxylic ester   Water       Carboxylic Acid       Alcohol  




In bacterial species such as Mycobacteria, Pseudomonas, Burkholderia TAG 
lipases have been shown to completely hydrolyse triacylglycerol substrates 
although ester bonds are more preferable (Jaeger et al., 1994) and they possess 
both lipolytic as well as esterolytic activity. Bacterial TAG lipases have also 
been found to share a common alpha/beta (α/β) hydrolase folding pattern. A 
large number of enzymatic assay methods using fluorescent substrates allow 
for the fluorimetric and spectroscopic detection of lipase activity. 
1.4 Alpha/Beta (α/β) Hydrolase fold family  
The alpha/beta (α/β) hydrolase fold is considered to be a common 
characteristic to a number of hydrolase enzymes of largely different 
phylogenetic origin and catalytic function (Ollis, Cheah et al. 1992). Each 
enzyme has a conserved alpha/beta (α/β) hydrolase core (fig.7b) consisting of 
alpha/beta sheet having 8 strands connected by helices. They all have a similar 
arrangement of a catalytic triad composed of nucleophilic serine charge relay 
network aspartate and proton carrier histidine (shown in fig.1. 6) which are the 
best-conserved structural features in the fold. The canonical α/β hydrolase fold 
is an eight-stranded and mostly parallel α/β structure (figure 1.6), (1.7a&b) 









                           Figure 1.6: Topology diagram of α/β hydrolase fold enzymes α Helices  
                                               and β strands are represented by black spheres and arrows,  
                                               respectively while catalytic triad members are highlighted by  




              






































The enzymes adopting alpha/beta hydrolase fold share no significant sequence 
similarity suggestive of a divergent evolution from a common ancestor. The 
members of alpha/beta (α/β) hydrolase fold family include: hydrolases, 
esterases, lipases, proteases, peroxidases, dehalogenases. 
 
1.4.1 Alpha/Beta (α/β) Hydrolase fold family in Mycobacteria   
Most members of the alpha/beta (α/β) hydrolase fold family are esterase/lipase 
enzymes that catalyse ester hydrolysis reactions (Schrag et al., 1997, Nardini 
et al., 1999). In Mycobacterium tuberculosis, out of the 250 genes encoding 
putative enzymes involved in lipid metabolism, 94 gene products would have 
the characteristic alpha/beta (α/β) hydrolase fold (Hotelier, Renault et al. 
2004), ESTHER database http://bioweb.ensam.inra.fr/esther) of which 47 are 
                Figure 1.7: (a) 3D structure  of  Pseudomonas fluorescens carboxyl esterase (PfCES) belonging to 
                                            α/β  hydrolase fold family revealing  mostly-parallel β sheets. (b) Superposition of  
                                            the conserved α/β hydrolase core of 9 representative α/β hydrolase fold enzymes  






annotated as esterases (ester hydrolases) and also including 24 lipid/ester 
hydrolase belonging to lip family (lipC to lipZ) (Cole, Brosch et al. 1998). The 
total M. tuberculosis functionally annotated genes and α/β hydrolase fold 


















Overall alpha/beta (α/β) hydrolase fold family members in Mycobacteria are 
mainly esterases/lipases suggesting an important structural link of this family 
of enzymes in mycobacterial lipid metabolism. 
 
               M. tuberculosis annotated genes 
            M. tuberculosis α/β hydrolase fold 
          (94 annotated genes) 
                  Figure 1.8: (a) Total M. tuberculosis functionally annotated genes. 
(b) 94 α/β hydrolase fold distribution in enzymes involved in mycobacterial lipid      





1.4.2 Mycobacterial Lipase gene family 
This sub-family of alpha/beta (α/β) hydrolase fold family comprises of 24 
genes annotated as putative esterases/lipases (lipC to LipZ) genes (Cole, 
Brosch et al. 1998) and all pose a catalytic triad with active site as 
nucleophilic serine showing a characteristic G-X-S-X-G sequence motif and 
are typically involved in various biological processes. Their probable function 
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1.4.2.1 Hormone-sensitive lipase sub-family (HSL) 
The hormone sensitive lipases are also known as triacylglycerol (TAG) lipases 
wherein their main function is to hydrolyse first fatty acid of triacylglycerol 
thereby yielding a diacylglycerol and a free fatty acid. They are, in turn, highly 
regulated enzymes catalysing the hydrolysis of lipids in adipocytes. In silico 
sequence analysis of mycobacterial lipase gene family members show 
significant sequence homology with hormone-sensitive lipase family having a 
characteristic HGG motif and a conserved active-site motif GDSAG. There 
are also 12 mycobacterial lipolytic enzymes which belong to the hormone-
sensitive lipase family of which 8 are derived from lip gene family namely 
lipF (Rv3487c), lipH (Rv1399c), lipI (Rv1400), lipN (Rv2970), lipR 
(Rv3084), lipT (Rv2045c), lipU (Rv1076), lipY (Rv3097c) and are of high 
functional importance.  
 
1.5 Issues and Problems with functional characterization of 
Mycobacterial   putative Esterases/Lipases 
 
A literature survey of the studies conducted in the past revealed that they were 
aimed at the functional characterization of mycobacterial esterases/lipases and 
reflects that the following issues and problems need to be addressed: 
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 Expression of mycobacterial esterase/lipase enzymes in their non-
natural (non-mycobacterial) expression systems such as E. coli.(Deb, 
Daniel et al. 2006) 
 Active conformation of enzymes lost after the purification step and 
consequently re-folding in E. coli (Canaan, Maurin et al. 2004). 
 Mycobacterial esterase/lipase enzymes such as Rv1399c (lipH) and 
Rv1400c (lipI) are insoluble and reported to form inclusion bodies 
(Canaan, Maurin et al. 2004). 
 Poor solubility of mycobacterial esterase/lipase makes it difficult to 
obtain an X-ray crystal structure. By far, only one 3D structure has 
been solved of mycobacterial esterase (lipW) (PDB ID: 3QH4) 
belonging to the lipase gene family. 
 
1.6 Tetrahydrolipstatin (Orlistat)  
Commonly called Orlistat and marketed by Roche pharmaceutical company 
under the name of Xenical is a semisynthetic hydrogenated derivative of 
naturally occurring lipase inhibitor lipstatin produced from Streptomyces 
toxytricini (Hochuli, Kupfer et al. 1987). It has been well characterized as an 
irreversible inhibitor of serine esterases (Hadvary, Lengsfeld et al. 1988) 
covalently modifying its biological target. It was identified originally as a 
specific inhibitor of pancreatic lipases and later developed as an anti-obesity 














Serine hydroxyl group of the catalytic triad of esterase/ lipase (Hadvary et al., 
1988). 
1.6.1 An FDA approved anti-obesity drug 
Orlistat was introduced in the pharmaceutical market by Roche under the 
name of ‘Xenical’ launched in the year 1998, was approved by the Food and 
Drug Administration (FAD), USA in 1999; it was represented as a ‘magic 
medicine’ for control of obesity for the sole reason that it inhibits potently and 
specifically breakdown of dietary triglycerides into absorbable fatty acids and 
monoglycerides (Cudrey, van Tilbeurgh et al. 1993) thereby resulting into 
30% fat absorption and hence consequential weight loss. 
1.6.2 An anti-cancer agent 
Recent studies have demonstrated that tetrahydrolipstatin (Orlistat) possess 
antitumor properties to prostate cancer cells due to its ability to induce 
inhibition of thioesterase domain of human fatty acid synthase (FAS) 
lipogenic activity which is found to be significantly up-regulated in many 
tumors and is an indicator of poor prognosis (Menendez, Vellon et al. 2005) 
       Figure 1.9: Chemical Structure of Tetrahydrolipstatin (Orlistat): arrow    






(Menendez et al., 2005). For example, 50% of breast cancers exhibit high 
expression levels of FAS. THL eliminates tumour cells by inducing apoptosis. 
1.6.3 An anti-mycobacterial agent 
In mycobacteria it has been shown that tetrahydrolipstatin (Orlistat) interferes 
with the cell wall formation of mycobacteria by decreasing mycolic acid 
synthesis (Kremer, de Chastellier et al. 2005), leading to a defective 
mycobacterial cell wall. Tetrahydrolipstatin is shown to inhibit Rv3802c an 
essential cell wall lipase enzyme which is probably involved in the mycolic 
acid biosynthetic pathway. Therefore tetrahydrolipstatin (THL) eliminates 
both mycobacterial and tumor cells by interfering with the lipid metabolism. 
 
1.7 Aims and Objectives of the present study:  
Carboxyl ester hydrolases (EC 3.1.1) comprising of evolutionarily related 
enzymes mostly belonging to hydrolases superfamily sharing a common α/β-
hydrolase protein fold and even though recent studies have revealed the 
findings suggestive of their pivotal role in disease manifestation by way of 
disruption of lipid metabolizing enzymes esterases/lipases and their pathways, 
yet only very few have been functionally annotated. This study therefore 
focuses attention on 4 putative mycobacterial lipases/esterase namely 
BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase), BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV 







1. To explore computational enzymology as an effective tool for  
     In silico characterization of mycobacterial putative esterases/lipases and 
identifying potential inhibitors. 
 
2. To investigate structural features of mycobacterial putative 
esterases/lipases and distinguishing lipolytic and non-lipolytic enzymes 
at the structural level itself. 
 
3. In vitro biochemical characterization of Mycobacterial esterases/lipases 
















2. Materials and Methods 
2.1 Molecular modelling  
2.1.1 Sequence analysis: 
The sequences of BCG_1460c (lipH probable lipase) (Uniprot Id: A1KII8), 
BCG_2991c (lipN probable lipase/esterase) (Uniprot Id: A1KMW4), 
BCG_2950 (tesA probable thioesterase) (Uniprot Id: A1KMS3) and 
BCG_3229 (lipV possible lipase) (Uniprot Id: A1KNK2) and their 
representative homologs were collected from the Uniprot database and  
multiple sequence alignments were performed using ClustalW (Larkin, 
Blackshields et al. 2007). This was found on the website 
[http://www.ebi.ac.uk/Tools/msa/clustalw2/] to identify the catalytic triad 
position, motifs and amino acid conservation. 
2.1.2 Comparative modelling: 
Structural homologs were identified using protein BLAST (Basic Local 
Alignment Search Tool) [ http://blast.ncbi.nlm.nih.gov/] against Protein Data 
Bank (PDB) database and were selected as templates based on the highest 
sequence identity presented. Swiss PDB viewer was used to thread the protein 
sequence on its structural homologs using MUSCLE package of Swiss PDB 
viewer (Guex and Peitsch 1997) and thereafter initial structural alignments 
were generated. Most favourable rotamers were added to the structure using 
the rotamer library embedded in Swiss PDB viewer and a modelling request 
was submitted to Swiss model server [http://swissmodel.expasy.org/]. There 
were top ten models generated for each protein and validated using 4 different 
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validation soft wares on NIH MBI Laboratory for Structural Genomics and 
Proteomics [http://nihserver.mbi.ucla.edu/SAVES/]. The evaluation of native 
protein fold on validated  3D structure models was performed using ProSA 
program (Wiederstein and Sippl 2007) and were  further refined by fragment-
guided molecular dynamic simulations FG-MD program (Zhang, Liang et al. 
2011) located at [http://zhanglab.ccmb.med.umich.edu/FG-MD/]. The refined 
model was energy minimized with GROMACS 4.0.7 package 
[http://www.gromacs.org/]. The resulting models were found to be 
energetically stable. The schematic representation of the steps involved in 
comparative modelling has been shown in figure 2.1  
 
 
Figure 2.1: Schematic diagram of steps involved in Molecular modelling 
(Source: adapted from http://swift.cmbi.ru.nl/teach/EMHOMX/EMBMOD_1.html) 
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2.2 Molecular Dynamics Simulations: 
Protein stability of the energy minimized models in a solvent system was 
assessed using molecular dynamics simulations and periodic boundary 
conditions were applied to the structures in three dimension. By adding the 
sodium ions and replacing the water molecules that are 3.5 Å from the protein 
surface, the net charge of the system was neutralized. Simulations were run for 
100 pico seconds with the solvent being equilibrated by a harmonic force 
constant 100 KJ nm
-2
 and the solute atoms were restrained. A production run 
of 10 nano second was used to check for the stability of protein models which 
is a plot of root mean square deviation of the backbone structure versus time. 
All simulations were performed at 300K temperature with velocity rescaling 
thermostat using Parrinello-Rahman barostat. The pressure was maintained at 
1 atmosphere and the long-range electrostatic interaction with cut-off 12 Å  
was calculated using Ewald (PME) summation method while the hydrogen 
bonds in the atoms were constrained with the linear constraint solver (LINCS) 
algorithm (Hess, Bekker et al. 1997) and  (Hess 2007). 
 
2.3 Virtual Ligand Screening: 
Computational docking of ligands in protein 3D structure model was 
performed using  Autodock Vina (Trott and Olson 2010). All essential 
hydrogen atoms, solvation parameters and the united atom charges were added 
using the help of AutoDock tools (Morris, Goodsell et al. 1998). Affinity grid 
maps were constructed via and with the aid of Autogrid program. The Vander 
Waals and electrostatic calculations were done using distance dependent 
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dielectric functions and parameters set functions of Autodock Vina. 
Computational docking simulations have been performed using the 
Lamarckian genetic algorithm and local search method (Solis and Wets, 
1981). The initial orientations, position, torsion angles of ligands were set 
randomly and during docking all rotatable torsions were released. For every 
docking experiment, 500 independent docking runs were performed involving 
30000 maximum energy evaluations and the population size was set to 200. 
The ligand 2D-structures were drawn in ChemDraw and the 3D structures of 
ligands were constructed with BUILDER module of molecular modelling 
program Insight-II assigning standard geometric parameters. The atomic 
charges were assigned to ligand using Amber potential. These ligands were 
then subjected to force field until the root mean square energy gradient 
became less than 0.005 Kcal/mol. All hydrogen atoms were added to the 3D 
structure models and Amber all-atom charges were assigned to the whole 
protein. 
The active site was then analysed using the CASTp program (Dundas, Ouyang 
et al. 2006) to recognize and characterize accessible pockets in the protein 3D 
model based on two parameters: the solvent accessible surface and the 
molecular surface. The active site was defined within a radius of 25 Å which 
covered 94% of the total residues in the protein ensuring that the size of the 
active site is sufficiently large enough to accommodate the whole ligand 
binding pocket and also allow for rotation and translation of ligands. The 














                        Figure 2.2: Schematic diagram of Computational Docking  
                                         (Source: (Jacob, Andersen et al. 2012)) 
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2.4 Bacterial strains and cultures 
2.4.1 Bacterial Strains  
M. bovis BCG Pasteur strain (ATCC 35734) and M. smegmatis (mc2155) were 
used in the experiments.  
 
2.4.2 Bacterial Culture Media 
Cultures of mycobacteria were grown under aerobic conditions. Inoculum was 
prepared from colony of growing cells and pre-culture was grown in 7H11 
media. Aerobic M. bovis BCG were grown in roller bottles with initial OD 
(optical density) measured at 600nm (OD600) of 0.5. The roller culture bottles 
were rotated at 1rpm for three days. 
Middlebrook 7H11: The mycobacterial cultures were grown using this culture 
media. Middlebrook 7H11 (Biomed Diagnostics, BD Difco Mycobacteria 
7H11 Agar, Catalogue No. 283810) supplemented with 10% oleic acid-
dextrose-albumin-catalase enrichment and 0.5% of glycerol (Biomed 
Diagnostics, BD Difco Middlebrook OADC Enrichment catalogue no.212351) 
at 37 °C. Whenever required, antibiotics were added to the M. bovis BCG 
culture media with the following concentrations: kanamycin (Sigma-Aldrich, 
USA) at 25 µg/ml and hygromycin (Roche,Germany) at 80 µg/ml . 
Middlebrook 7H9 broth: This liquid media was used for growing 
mycobacterial cultures. The Middlebrook 7H9 (Biomed Diagnostics, BD 
Difco Mycobacteria 7H9 Broth, Catalogue No. 2713100)  supplemented with 
0.2% glycerol, 0.05% Tween-80 and 10% (v/v) Albumin-Dextrose-Saline 
(ADS: 950ml dH20, 8.1g NaCl, 50g Bovine Serum Albumin Fraction V, 20g 
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D-dextrose). The whole medium was filter sterilized with o.22µM filter and 
stored at 4°C until further use. 
 
2.4.3 Glycerol stock of bacteria 
M.bovis BCG and M. smegmatis: Glycerol stocks of cultures were prepared by 
re-suspending in Middlebrook 7H9 broth containing 25% glycerol (v/v) and 
stored as 0.5ml aliquots at -80ºC. 
 
2.5 Cloning Procedures 
 
2.5.1 Genomic DNA Isolation (Mycobacteria) 
 
The mycobacterial cells were grown to an OD of 0.8 (measured at 600nm), 
cells were then harvested by centrifuging at 3000g for 10mins at 4°C, washed 
with PBS-T (0.05% of Tween-80). The pellet obtained was re-suspended in 
600µL buffer having 3% SDS, 1mM Tris-HCL with 100Mm sodium chloride. 
Cells were transferred to tubes having silica beads (0.1mm in diameter) and 
then displaced using bead beater at 50rpm for 5mins at 4°C. Mixture of 
phenol/isoamyl alcohol/chloroform in the ratio (49:2:49 v/v/v) was added and 
then final volume made up to 2 X. Upon centrifuging at 16,000g for 5mins at 
4°C the aqueous phase was collected then washed using 500µl of 70% ethyl 
alcohol. Supernatant was then recovered pellet was dried at room temperature 
for 10mins. Precipitated DNA pellets were then re-suspended in 100µl of TE 





2.5.1 Preparation of Over-expression Plasmids 
 
The putative esterases and/or lipases genes namely, BCG_1460c (lipH 
probable lipase), BCG_2991c (lipN probable lipase/esterase), BCG_2950 
(tesA probable thioesterase) and BCG_3229 (lipV possible lipase) were 
amplified by using PCR with genomic DNA isolated from M. tuberculosis 
H37Rv with primer details as given below: 
Note: Restriction sites are underlined: forward BglII; reverse HindIII 
 
The BglII and HindIII sites of the E.coli-Mycobacterium shuttle vector 
pMV262 were inserted with PCR fragments under a constitutive HSP60 
promoter. 
 
Primers used for gene cloning and amplification 
BCG_1460c    
(lipH) 
Forward GCAGATCTATGACCAAGAGTCTGCCAGGT 




Forward GCAGATCTATGACCAAGAGTCTGCCAGGT   
 Reverse GCAAGCTTTCAAACCCGGCTAAGGTGCGC   





















2.6 Mycobacterium bovis BCG competent cell preparation, transformation 
(electroporation) and selection of transformants 
 
Inoculum from growing BCG cells was grown in 7H9 broth media (no 
antibiotics) the culture was grown to ~0.8 optical density (OD600). The culture 
was centrifuged at 3700rpm and cells were re-suspended in 1ml of 0.05% 
tween80. 200 µl aliquot was stored at -80ºC. M.bovis BCG cells grown up to 
an OD600. Cuvettes (Biorad ) with an electrode gap of 2mm were used for 
electroporation and 1µl of plasmids was added to each cuvette and mixed 
gently. Using Biorad gene pulser Xcell and pulsed at 2500V, 800 ohms, 25µF 
transformants carrying the plasmids were selected on 7H11 plates containing 
suitable antibiotic (hygromycin) the plates were left at 37 ºC to allow for 
colonies to appear and thereafter an incubation period was allowed for four 
weeks to have them grown until a visual turbidity was reached. 
 
2.7 Preparation of Whole cell lysate (WCL) 
The mycobacterial cultures were grown on Middlebrook 7H11 (Biomed 
Diagnostics, BD Difco Mycobacteria 7H11 Agar, Catalogue No. 283810) 
supplemented with 10% oleic acid-dextrose-albumin-catalase enrichment and 
0.5% of glycerol) (Biomed Diagnostics, BD Difco Middlebrook OADC 
Enrichment catalogue no.212351) for four weeks. Bacterial colonies were 
harvested and washed thrice with phosphate buffered saline with tween80 
(PBST) and cells were vortexed. Bacterial cells were lysed using probe 
sonicator with the following parameters: 60% amplitude, 5 mins, 10 seconds 
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pulse on 5 seconds off and the lysed cells were centrifuged at 14000rpm; 
protein was estimated using the Lowry’s protein estimation method. 
2.8 Fluorescent click chemistry 
Samples were prepared for click reaction by washing the M. bovis BCG cells 
with phosphate buffered saline with tween80 (PBST) thrice and once with 
phosphate buffered saline (PBS) and centrifuged at 3500g for 15 minutes at 4 
ºC thereafter lysed in phosphate buffered saline (PBS) at 50% amplitude. 
100µg of protein was used for the reaction in which drug was incubated with 
protein. The amounts of reagents used for each reaction have been described 




2.9 Gel Electrophoresis 
Samples were prepared for the gel run by adding 600 µl of acetone and left at  
-20 ºC for 24 hours cells were centrifuged at 14,000 rpm then washed with 200 
µl of methanol. Subsequently, cell lysis was done using sonicator with the 
following parameters: 60% amplitude, 5 mins, 10 sec pulse on/ 5 sec off  after 
cell lysis 50 µl of SDS dye was added and boiled at 95 ºC for 5 mins. Equal 
amounts of 10 micro gram protein was separated on 12% SDS-polyacrylamide 
gel, ran at 120 V for 110 mins followed by in-gel fluorescence scanning with 
Typhoon 9410 Variable Mode Imager scanner (GE Amersham, UK) . The 
cyc3/cyc5 scan protocol adopted was as follows: 3*10
8
 cells for each staining 
Table 2.1 Click reaction  
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and washed once with phosphate buffered saline with 0.05%tween80 (PBST) 
and centrifuged at 3000g for 5mins at 4 ºC. Subsequently washed with 
phosphate buffered saline  (PBS)  after which 10ng of LD540 dye was added 
and incubated for 10 mins at room temperature. 500µl of 4% formaldehyde 
was added and tubes were centrifuged at 3000g for 5mins at 4 ºC. Cells were 
again washed with phosphate buffered saline (PBS) and permealized with 500 
µl of 0.25% Triton-X 100 in PBS for 15 mins . 
 
2.10 Enzymatic Assays 
The enzymatic assays were performed with whole cell lysates of BCG cells 
overexpressing proteins BCG_2991c (lipN probable lipase/esterase), 
BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV possible lipase) 
using p-nitrophenyl  (pNP) esters (Sigma Aldrich) with carbon chain lengths 
of C2, C4 and C16. The pNP release was measured at 400nm by using a 96 well 
plate spectrophotometer. The enzymatic reaction was performed with 225µl of 
NaDC tris buffer (Tris 15.14mg, Nacl-0.8766g, Sodium deoxycholate -1mM 
(20.7mg) measured and dissolved in 25ml of milliq water and the pH of the 
whole medium was adjusted to pH 8.0). This was added to each reaction along 
with 2.5µg/µl of protein concentration and 1mM of pnP-C2/C4/C16 substrate 
incubated for 30mins at 37 ºC. The final volume of each well was kept at 250 
µl and the absorption was measured at 400nm using a 96 well plate 
spectrophotometer and readings were recorded at 0, 1, 2.5, 5 and 10 minutes 
time points. All reactions were performed in triplicates. The schematics of 



















2.11 Inhibitor assays 
Fresh stock of frozen cells at -80 ºC was used for every experiment. The vials 
were thawed in ice for 30 minutes and fresh substrate p-nitrophenol butyrate 
(pnP-C4) used in the inhibition experiments was prepared to 1mM 
concentration (dissolving 2µl of pnP-C4 in 9.7ml of dimethyl sulfoxide), 
buffer NaDC tris buffer ( Tris 15.14mg , Nacl-0.8766g, Sodium deoxycholate 
-1mM (20.7mg) measured and dissolved in 25ml of milli-Q water and the pH 
of the whole medium was adjusted to pH 8.0). 225 µl of NaDC tris buffer, 
2.5µg of protein and different concentrations of inhibitors such as THL 
   







 as substrate 
 Stock Conc. Working conc. Volume 
Buffer - - 225µl 
Overexpression 
protein whole cell 
lysate 
- 2.5µg  1µl 
pNP substrate 10 mM 1 mM 25 µl 
 
 Table 2.2 Concentrations of reagents used  
 
                  Figure 2.3: Scheme of pNP Assay 
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(tetrahydrolipstatin) E600 (diethyl-p-nitrophenylphosphate) was used from 
.01µM to 100µM (volume kept at 1µl) were added to each well of 96 well 
plate. DMSO (dimethyl sulfoxide) concentration was maintained at 0.004% in 
each well, incubation time was 30 mins at 37 ºC and the absorption was 
measured at 400nm using a 96 well plate spectrophotometer. Measurement 
readings were recorded at 0, 1, 2.5, 5 and 10 minutes time points. All reactions 
were performed in triplicates. The template indicating the component of each 













3.1 Molecular modelling of protein 3D structures 
In order to understand the insight as well as structural details and characterize 
four putative esterases/lipases belonging to (α/β) hydrolase family viz. 
BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase), BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV 
possible lipase), a computational prediction of their ligand specificity for 
catalytic triad was performed. 3D model structures were generated using 
molecular modelling protocol, at first we validated the molecular modelling 
protocol by predicting in silico the 3D structure of protein named thioesterase 
domain of fatty acid synthase (Human FAS-TE) (Protein Databank ID: 2PX6) 
whose X-ray 3D structure is well known this acted as our positive control. 
Molecular overlay of the modelled 3D structure with known 3D structure of 
FAS-TE (figure 3.1 (a)) revealed that in silico modelled FAS-TE structure 
could mimic the known FAS-TE structure reasonably well with a carbon alpha 
backbone (Cα) root mean square deviation (rmsd) of 0.192Å (figure 3.1b) and 
an acceptable statistics in Ramachandaran plot (Suplatov, Besenmatter et al. 
2012). The 3D model structure of BCG_1460c (lipH probable lipase) was 
generated based on structural homologues of 3 thermophilic esterases with 
significant sequence identity in the range of 40 to 44% namely 
Alicyclobacillus acidocaldarius (carboxyl esterase Est2) (Protein data bank 
ID: 1U4N) with 44% sequence identity, Archaeoglobus fulgidus (carboxyl 
esterase AFEST) (Protein data bank ID: 1JJI)  with 41% sequence identity and 
bacterial acetyl esterase (HerE) (Protein data bank ID: 1LZL) had 40% 
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sequence identity. It was also revealed that BCG_2950 (tesA probable 
thioesterase) has 2 bacterial thioesterases structural homologues with sequence 
identity in the range of 31-33% namely Streptomyces coelicolor (Thioesterase) 
(Protein data bank ID: 3QMV) having 33% sequence identity and thioesterase 
from Amycolactopsis mediterranei (Protein Data Bank ID: 3FLB) had 31% 
sequence identity with protein sequence of BCG_2950 (tesA probable 
thioesterase). For BCG_2991c (lipN probable lipase/esterase) the BLAST 
searches found that it has structural homologs in 2 carboxyl esterases with 
sequence identity ranging from 39% to 41% : Hormone sensitive lipase-like 
Carboxylesterase from Sulfolobus Tokodaii (Protein data bank ID: 3AIO) 
(41%) , carboxyl esterase (Est2) Alicyclobacillus acidocaldarius (Protein data 
bank ID: 2HM7) (39%) while BCG_3229 (lipV possible lipase) shows 
structural homologs in the sequence identity range of 27% to 31% with two 
esterases: thioesterase domain from Curacin biosynthetic pathway (Protein 
data bank ID: 2HM7) (31%) and Rv0045c from Mycobacterium tuberculosis 
(Protein Data Bank ID: 3P2M).                                                                   
       
Figure3.1: (a) 3D structure Overlay of FAS-TE modelled structure over FAS-TE known X-ray 
3D structure in protein data bank (2PX6) (b) Cα – backbone overlay r.m.s.d 0.192Å (red: in 
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Figure3.2 3D structure models: (a) BCG_2950 (tesA probable thioesterase) (b) BCG_1460c 
(lipH probable lipase) (c) BCG_2991c (lipN probable lipase/esterase) (d) BCG_3229 (lipV 









The 3D structure models (figure 3.2) indicated that all 4 putative 
esterases/lipases namely BCG_1460c (lipH probable lipase), BCG_2991c 
(lipN probable lipase/esterase), BCG_2950 (tesA probable thioesterase) and 
BCG_3229 (lipV possible lipase) are globular proteins similar to other 
alpha/beta (α/β) hydrolase enzymes and consist of 11 α- helices and a central 
β-sheet core containing 6 parallel β- strands. The GXSXG motif characteristic 
of esterases/lipases was found to be conserved in all 4 enzymes viz.  
BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase), BCG_2950 (tesA probable thioesterase) and  BCG_3229 
(lipV possible lipase) whereas the invariant motif HGG of hormone sensitive 
lipase family was conserved in BCG_1460c (lipH probable lipase), 
BCG_2991c (lipN probable lipase/esterase). The catalytic triad was known to 
be composed of nucleophilic serine which is the active site, a charge relay 
network aspartate and proton carrier histidine. The structure validation report 
from four different validation soft wares on NIH MBI laboratory 
[http://nihserver.mbi.ucla.edu/SAVES/] for structural genomics and 
proteomics are shown in fig.3.3 whereas angle distribution of amino acids in 
3D structure models is shown in fig.3.4 
Figure 3.3: Structure validation report from 4 different validation soft wares 










    Figure 3.4: Ramachandran plot statistics of backbone dihedral angle distribution  





Fig. 3.5 illustrates protein structure analysis from PROSA (protein structural 
analysis) web server as depicted below whereas fig 3.6 illustrates molecular 
dynamic simulation on validated 3D structure models. 




 Figure 3.5: Protein structure analysis from PROSA (protein structural  
 analysis) web server shows 3D structure models have Z-score -6.47 in the  
 acceptable range for near native conformation of  X-ray crystal structures 
                        
 
  Figure 3.6: Molecular dynamic simulations of modelled 3D structures  
  show that the energy minimized 3D model structures are energetically stable 
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3.2 Molecular Structure based Ligand Screening 
In order to identify natural substrates/potential inhibitors and to characterize 
the substrate specificity of  BCG_1460c (lipH probable lipase), BCG_2991c 
(lipN probable lipase/esterase), BCG_2950 (tesA probable thioesterase) and 
BCG_3229 (lipV possible lipase), a structure based virtual ligand screening 
was performed. At first a in silico library of potential ligands was constructed 
based on literature review of substrate preferences of well characterized 
carboxyl esterases in mycobacterial species. This resulted into a in silico 
ligand library of natural substrates such vinyl esters of varying acyl chain 
lengths from short chain vinyl acetate (C2) to long chain palmitate (C16) along 
with triacylglycerol substrates (TAGs) varying from short chain TAGs such as 
tripropionate (C3) to long chain TAGs trioleate (C18) with potential inhibitors 
of serine hydrolases such as THL, PMSF and E600. 
The in silico potential ligand library was thereafter screened using molecular 
docking engine Autodock (Trott and Olson 2010) into the active site of 3D 
structures of BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase), BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV 









3.2.1 Evaluation of Ligand Screening Results 
The ligand screening results were evaluated based on two scoring functions:  
a.) Ligand binding affinity/energy towards its target enzyme. 
b.) Distance to active site (serine in all cases) which describes a near 
attack conformation (NAC) (Hur, Bruice et al. 2003) of the ligand in 
the binding site.  
The enzyme-ligand docked structures were ranked by frequency binding in 
near attack conformation obtained from 500 independent docking runs (p-
value <0.05). The ligand specificity to its target enzyme was confirmed based 
on the highest binding affinity and the least distance to active site (serine). A 
threshold for an acceptable near attack conformation of ligand distance to 
active site should be less than 3.5Å (Suplatov, Besenmatter et al. 2012) while 
the ligand binding affinity should fall within the range of -4 Kcal/mol to -8 














Figure 3.7: Short (C2) to long (>C12) acyl chain ester ligands screening results, highlighted 
circle in red show most favourable ligand (highest ligand specificity) based on its lowest  
energy and least distance to active site (Serine). Graphs showing the ligand specificity 





    
(a)  (b) 
(c)  (d) 
lipH  lipN  
lipV  tesA  
       Table 3.1 Summary of potential substrates screening results 
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Based on the two criteria evaluation of structure based virtual screening, 
results revealed that BCG_1460c (lipH probable lipase) favours docked near 
attack conformations with short acyl chain esters from vinyl butyrate (C4) up 
to vinyl laurate (C12) and short chain TAGs such as tripropionate having 
identical fatty acyl chains (3:0/3:0/3:0) and tri butyrate (4:0/4:0/4:0)  (table 
3.1) with highest ligand specificity for vinyl caproate (C6) and a binding 
affinity of -5.11 Kcal/mol and 2.5Å distance to active site (serine) (figure 
3.7(a)). For BCG_2991c (lipN probable lipase/esterase), it had a similar 
binding affinity towards short acyl chain vinyl esters and TAGs ranging from 
vinyl butyrate (C4) up to vinyl lauraterate (C12) and tripropionate having 
identical fatty acyl chains (3:0/3:0/3:0) to tri butyrate (4:0/4:0/4:0) (table 3.1) 
with highest ligand specificity for vinyl butyrate (C4) and a binding affinity of 
-5.9 Kcal/mol with  2.62 Å distance to active site (serine) (figure 3.7(b)). On 
the other hand BCG_3229 (lipV possible lipase) also depicted ligand 
preference towards  short chain vinyl esters such as vinyl butyrate (C4) up to 
(C14) and TAGs ranging from tripropionate having identical fatty acyl chains 
(3:0/3:0/3:0) to tricaproate (6:0/6:0/6:0) (table 3.1) with highest ligand 
specificity for vinyl caproate (C6) having a binding affinity of -6.0 Kcal/mol 
and 1.92Å distance to active site (serine) (figure 3.7(c)). However, 
interestingly BCG_2950 (tesA probable thioesterase) showed preference for 
very long chain lengths (>C16) with the highest ligand specificity for 
phthiocerol (C28) having a binding affinity of -7.2 Kcal/mol and 1.02Å 
distance to active site (serine) (figure 3.7(d)). 
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The screening for potential inhibitors resulted in the prediction of THL 
(tetrahydrolipstatin) as the most potent inhibitor of BCG_1460c (lipH probable 
lipase), BCG_2991c (lipN probable lipase/esterase), BCG_2950 (tesA 







lipH THL Lipase 
inhibitor 
1.82 Å    -7.10 
lipH E600  Lipase 
inhibitor 
2.02 Å  -6.70 
lipH PMSF  Protease 
Inhibitor 
2.12 Å -5.60 
lipN THL Lipase 
inhibitor 
2.08 Å    -6.5 
lipN E600  Lipase 
inhibitor 
2.23 Å  -5.2 
lipN PMSF  Protease 
Inhibitor 
2.32 Å -4.9 
tesA THL Lipase 
inhibitor 
1. 91Å    -7.2 
tesA E600  Lipase 
inhibitor 
2.37 Å -5.6 
tesA PMSF  Protease 
Inhibitor 
2.38 Å -5.4 
lipV THL Lipase 
inhibitor 
1. 84Å    -7.6 
lipV E600  Lipase 
inhibitor 
2.06 Å -5.2 
lipV PMSF  Protease 
Inhibitor 
2.62 Å -4.4 
Table 3.2 Summary of potential inhibitors ligand screening results  
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probable thioesterase) and BCG_3229 (lipV possible lipase) as compared to 
E600 and PMSF as shown above in table 3.2. 
3.3 Over expressing mycobacterial putative esterases/lipases. 
BCG_1460c (lipH), BCG_2991c (lipN), BCG_2950 (tesA) and BCG_3229 
(lipV) were found to be over expressed and successfully transformed. The 
fluorescent gel image (fig.3.8) clearly demonstrates an over-expression in 
protein levels of BCG_1460c (lipH probable lipase) and BCG_2950 (tesA 
probable thioesterase) having molecular weight of 34.0 kDa and 29.0 kDa 


















Figure 3.8: SDS-PAGE fluorescent gel image showing change in protein 




                                                   
3.4 Biochemical Characterization  
3.4.1 Enzymatic Assays 
To characterize the activities of BCG_1460c (lipH) and BCG_2950 (tesA) 
enzymes, the whole cell lysates of over expressed BCG_1460c (lipH) and 
BCG_2950 (tesA) were assayed with synthetic vinyl ester substrate para-
nitrophenol-butyrate (C4). A ~2.5 times fold change was observed in the 
absorption (measured at 400nm) for BCG_1460c (lipH) as compared to wild 
type M. bovis BCG (non-over expressed) (fig.3.9)  
 
 
Figure 3.9: Enzymatic assay with whole cell lysate of overexpressed  
BCG_1460c (lipH) and BCG_2950 (tesA) using substrate para-nitro 




Within 2.5 mins of the enzyme reaction almost 80% of substrate para-
nitrophenol-butyrate (C4) was converted into products i.e. butyric acid and 
para-nitrophenol the latter showing maximum absorption at 400 nm. However, 
overexpressed BCG_2950 (tesA) indicated no change in absorption and was 
lesser compared to the wild type (non-overexpressed) (fig3.9). In order to 
ensure adequate accuracy, the enzymatic assay was performed with two 
biological and two technical replicates. 
 
3.4.2 BCG_1460c (lipH probable lipase) shows short-chain esterase 
activity 
 
To further investigate the substrate specificity of BCG_1460c (lipH), enzyme 
assay was performed using synthetic substrates of vinyl ester substrates 
including short–chain esters such as para-nitrophenol-acetate (C2) and para-
nitrophenol-butyrate (C4) and long-chain ester para-nitrophenol-palmitate 
(C16) with whole cell lysate of over expressed BCG_1460c (lipH).  
The assay results revealed that BCG_1460c (lipH probable lipase) shows a 
short-chain esterase activity towards para-nitrophenol-acetate (C2) and para-
nitrophenol-butyrate (C4) (fig3.10) and there was no activity observed towards 











3.5 THL (Tetrahydrolipstatin) strongly inhibits short-chain esterase 
activity of BCG_1460c (lipH) 
Inhibition experiments were performed using well known lipase inhibitor 
tetrahydrolipstatin (THL) and E600 (diethylparanitrophenyl phosphate) the 
latter being a specific inhibitor of catalytic site serine were assayed with whole 
cell lysate of over expressed BCG_1460c (lipH) with the choice of substrate 
being p-nitrophenol butyrate (pNP-C4) since all our previous enzymatic 
reactions of over expressed BCG_1460c (lipH) were most stable with pNP-C4. 
Tetrahydrolipstatin (THL) was found to strongly inhibit the short-chain 
Figure 3.10: Enzymatic assay of over expressed BCG_1460c (lipH) with  
varying acyl chain length substrates para-nitrophenol-acetate (C2),  
butyrate (C4), palmitate (C16) (** n=2 biological replicates) 
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esterase activity of BCG_1460c (lipH) as indicated by its IC50 value of 
0.12±0.035µM (fig3.11) and E600 (diethylparanitrophenyl phosphate) 
inhibitor having an IC50 value of 0.399±0.172µM (fig3.12). All the inhibition 
assays were performed with 2 biological and 2 technical replicates. Of note, 
IC50 values are expected to be even lower for purified BCG_1460c (lipH) 




Figure 3.11: THL (Tetrahydrolipstatin) inhibitor assay (IC50) towards  
BCG overexpressing BCG_1460c (lipH) from log phase culture (*** n=3)  
 
Figure 3.12: E600 (diethylparanitrophenyl phosphate) inhibitor assay  
(IC50) towards BCG overexpressing BCG_1460c (lipH) from log phase 




3.6 Predicted binding mode model of THL inhibition in BCG_1460c (lipH) 
3D structure 
 
To understand at the structural level THL inhibition of short-chain esterase 
activity of BCG_1460c ligand docking experiments were performed. 3D 
structure model of lipH is shown in fig.3.13 (a) with its potential docked 
substrate (Vinyl caproate) and inhibitor (THL) predicted from in silico ligand 
screening results. Interactions of substrate (Vinyl caproate) within binding 
pocket have been shown in fig.3.13 (a) while interactions of THL 
(tetrahydrolipstatin) within the binding pocket shown in fig. 3.13(b) revealed a 
near attack conformation of β-lactone ring from the active site serine further 
the molecular overlay of catalytic triad (serine, histidine, aspartate) from 









Amino acid interaction Ligand binding pocket (a) lipH + substrate  
Area        298.1 Å 
Volume   348.4 Å 
 Length    14.21Å 






















Distance to active site 
























Figure 3.13 (a & b). Three dimensional model of lipH structure depicting the core α/β-
hydrolase fold with catalytic triad (yellow). The 3D model is docked with lipH probable 
substrate, vinyl caproate (blue) and probable inhibitor, THL (red). The insert (middle) 
depicts the catalytic triad and other amino acids interacting with docked ligand. And the 
binding energy of ligand binding pocket is represented on far right to show that area, 
volume and width of the pocket decide the specificity of ligand conformation and the 
folding pattern. (c) Overlay of catalytic triad docked with substrate (blue) and with THL 
(red). The change in C—C atom r.m.s.d value of lipH catalytic site triad with substrate and 
THL is mentioned at the bottom of the figure. 
(c) lipH catalytic site overlay  
(b) lipH + THL  Amino acid interaction Ligand binding pocket 
Binding 
Affinity/Energy 
 -7.10 Kcal/mol 
Distance to active 
site (Serine) 1.82 Å 
 
Area   533.2 Å 
Volume  579.5 Å 
Length    26.05 Å 
Width    9.56 Å 
Ser162 His290 Asp260 



























that there is only a very small root mean square deviation (difference) of the 
catalytic triad restudies with active site serine having root mean square 
deviation of 0.567 Å, histidine 0.392 Å and aspartate 1.012 Å (fig. 3.13(c)). 
Therefore, it was predicted that THL inhibitor binds in the substrate pocket of 
BCG_1460c (lipH) where the hexanoyl (C6) arm of THL binding to the 
substrate pocket may well be mimicking the short-chain substrate (vinyl 
caproate C6) binding in the ligand binding pocket of BCG_1460c (lipH) this 
hypothesis has been discussed in details in the discussion section which would 
now follow.   
 
4. Discussion 
Mycobacterium tuberculosis incorporates an unusually high number of genes 
in its lipid metabolism (Cole et al., 1998) and it is known that there are 250 
genes encoding putative lipid synthesis/degrading enzymes as compared to 
only 50 genes in E.coli having a similar genome size. Recent studies have 
suggested that success of Mycobacterium tuberculosis pathogen relies on its 
exceptional capacity to latently infect and re-infect its host which is mainly 
attributed to its lipid metabolism. The mycobacteria prior to entering into non-
replicating state have been shown to accumulate intracellular lipids (TAGs) 
(Garton, Christensen et al. 2002). The studies of Coles group, in 2008 (Cotes, 
Bakala N'goma J et al. 2008) have reported that during the mycobacterial re-
infection cycle i.e. exit from non-replicating state, the bacteria hydrolyses its 
intracellular lipid deposits (TAGs) using hydrolytic enzymes like 
esterases/lipases. Sequence analysis has revealed 31 of such putative lipolytic 
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enzymes out of which 24 have been classified under lip family as putative 
esterases/lipases but very few have been functionally annotated and the 3D 
structure of only one esterase lipW (PDB ID: 3QH4) has been reported to have 
been established so far. Our results from this study conducted in 
Mycobacteirum bovis BCG provides insights into molecular structure of 4 
putative mycobacterial esterases/lipases namely BCG_1460c (lipH probable 
lipase), BCG_2991c (lipN probable lipase/esterase), BCG_2950 (tesA 
probable thioesterase) and BCG_3229 (lipV possible lipase) and predicting 
natural substrates and a potent inhibitor THL (tetrahydrolipstatin) by structure 
based virtual ligand screening apart from biochemical characterization of 
short-chain esterase activity BCG_1460c (lipH probable lipase) inhibited by 
THL (tetrahydrolipstatin). However, detailed results would now be discussed 
in following sections 
4.1 In silico Studies: 
4.1.1 Role of Virtual Screening in Antibacterial Drug Discovery 
The golden era of antibacterial chemotherapy began in the 1950s and by  the 
advent of 1970s almost all major classes of antibacterial agents currently in 
use (Simmons, Chopra et al. 2010) were discovered this was a major scientific 
and medical achievement that had enormous benefits for treatment of deadly 
infectious diseases (caused by bacteria) affecting the human race. However, 
the emergence of widespread global occurrence of bacteria resistant to the 
antibiotics and synthetic drugs threatens to reverse our ability to treat 
infectious diseases (Chopra 2013). Furthermore the new drugs in 
pharmaceutical pipelines are mostly derivatives of older classes of 
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antibacterial currently in use and therefore making them more prone to the 









As shown in figure 4.1 the most critical step in the process of antibacterial 
drug discovery is the viable lead identification step. The early predictions on 
the lead quality set the stage for the subsequent efforts to enhance therapeutic 
efficacy through selectivity, pharmacokinetics, potency and toxicity (Polgar 
2007). In a retrospective view of the antibacterial drug discovery process, the 
essential step of lead identification was mainly driven by in vivo 
methodologies, but the limitations of in vivo models were later found to be 
major factors in evaluating attrition rates which therefore suggested 
researchers to introduce rational approaches such as structure based virtual 
screening and in vitro methodologies at the frontline of drug discovery 
campaigns. Virtual screening (VHTS) combines both rational approaches such 
Figure 4.1 Showing principal antibacterial drug discovery strategies (above 
the date line) in the period from 1940 to the present day and supporting  
technologies (below the date line). The golden era of antibacterial drug  
discovery(∼1945–76) is also indicated (Adapted from Chopra 2013)  
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as structure-based screening with high throughput approaches (HTS). The 



















Figure 4.3 Detailed workflow of a high throughput virtual screening (VHTS) 
                      (Source: http://www.molfunction.com/virtual.htm ) 
 




4.1.2 Concepts, Feasibility and Drawbacks of Virtual Screening 
Virtual screening is a strategy aimed at bringing together a more focused 
approach to high throughput screening by applying rational computational 
analysis to a subset of compounds considered to be appropriate for a given 
receptor. It is quite clear that this strategy implies that there is some starting 
point information which is available pertaining to either the nature of the 
binding site of receptor and/or ligand type that would be expected to 
favourably bind within the active site of the receptor. However, it should be 
realized that virtual screening itself combines a variety of computational 
screens, which encompasses simplistic to sophisticated algorithms which 
explore different types of information describing receptor. Similarly, it can be 
used to produce either a highly focused compound subset (for instance if only 
the close structural analogs of a lead compound are of interest) or a highly 
open ended subset (for instance a constraint on size, described by molecular 
weight, may be applied), although this largely depends on the objectives and 
interests of the HTS project. 
 
4.1.3 Molecular 3D Structure Modelling and Virtual Ligand Screening  
In our in silico study, we have demonstrated 3D structure models of 
BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase), BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV 
possible lipase), with an accuracy of  >95% having near native conformation 
of energetically stable and validated 3D structure models. 
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Partially modelled 3D structure of Rv1399c (BCG_1460c lipH) in 
Mycobacterium tuberculosis has been reported in the study of Canaan group in 
2004 (Canaan, Maurin et al. 2004) and Rv2928 (BCG_2950  tesA) from 
Chavadi group in 2011 (Chavadi, Edupuganti et al. 2011) whereas in the 
present study we have predicted complete domain modelling of BCG_1460c 
(lipH probable lipase), BCG_2950 (tesA probable thioesterase), BCG_2991c 
(lipN probable lipase/esterase), and BCG_3229 (lipV possible lipase). 
We have uniquely extended the concept of molecular modelling to a structure 
based ligand screening to predict and understand the ligand specificities 
particularly those pertaining to  BCG_1460c (lipH probable lipase), 
BCG_2950 (tesA probable thioesterase), BCG_2991c (lipN probable 
lipase/esterase), and BCG_3229 (lipV possible lipase). Our results suggest that  
BCG_1460c (lipH probable lipase), BCG_2991c (lipN probable 
lipase/esterase) and BCG_3229 (lipV possible) show an inclined tendency of 
ligand affinity towards short-chain vinyl esters such as vinyl butyrate (C4) and 
vinly caproate (C6) whereas for triacylglycerol (TAGs) substrates were found 
to be tripropionate having identical fatty acyl chains (3:0/3:0/3:0) to 
tricaproate having identical fatty acyl chains (6:0/6:0/6:0). Our results were 
performed with 500 independent docking runs involving 300000 maximum 
energy evaluations to achieve desired statistical significance (p-value<0.05).  
Further our molecular modelling and ligand screening (docking) protocols 
were validated to serve as effective computational tools towards in silico 
characterization of mycobacterial putative esterases/lipases.  
 70 
 
  4.1.4 Predicted binding mode model of THL inhibition in BCG_1460c 
(lipH) 3D structure 
Our results predict the binding mode and ligand interactions of THL 
(tetrahydrolipstatin) within the ligand binding pocket of BCG_1460c (lipH) 
(fig.3.13). 3D structure and molecular overlay of catalytic site in fig.3.13(c) 
shows a very small root mean square deviation (difference) of substrate bound 
and inhibitor bound catalytic triad residues with active site serine having an 
root mean square deviation of 0.567 Å, histidine 0.392 Å and aspartate 1.012 
Å. This observation tends to suggest that THL binds within the substrate 
pocket of BCG_1460c (lipH). Further it was also found that β-lactone ring of 
THL known to interact covalently with the active site serine of 
esterases/lipases adopts near attack conformation within the substrate binding 
pocket of BCG_1460c (lipH) and is located at a distance of 1.82 Å from active 
site serine (hydroxyl group-OH). This again is a favourable indicator of a 
possible nucleophilic attack by active serine on the carbonyl carbon of β-
lactone ring. Further comparisons between ligand interactions of short-chain 
substrate vinyl caproate (C6) and inhibitor THL tempted us to predict that 
hexanoyl (C6) arm of THL might well be mimicking short-chain vinyl 
caproate (C6) substrate specificity of BCG_1460c (lipH) within its substrate 
pocket. 
4.2 In vitro Studies: 
4.2.1 BCG_1460c (lipH probable lipase) is a short-chain carboxyl esterase 
 
Our in vitro biochemical assays suggest a short-chain esterase activity of 
BCG_1460c (lipH probable lipase) (fig 3.13) which correlates well with the 
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findings of a  study conducted by Canaan et al., 2004 in Mycobacterium 
tuberculosis on Rv1399C( lipH putative lipase) where they have cloned, 
expressed and folded the enzyme in E.coli. This is not the natural environment 
(non-mycobacterial) and the enzyme was found to be insoluble, expressed as 
inclusion bodies and the active state was lost after the purification step and 
was consequently re-folded in E.coli using an alternative in vitro protocol. In 
this study we performed enzymatic assays with whole cell lysates of 
Mycobacterium bovis BCG over-expressing BCG_1460c (lipH probable 
lipase) using synthetic substrates and results suggest a short-chain esterase 
activity of  BCG_1460c (lipH probable lipase) with para-nitrophenyl actetae 
(C2) and para-nitrophenyl actetae (C4) (fig.4.1). We also transformed 
Mycobacterium smegmatis MC2 with BCG_1460c (lipH probable lipase) 
over-expression clone and our biochemical assays again showed a short-chain 
esterase activity of BCG_1460c (lipH probable lipase) in Mycobacterium 








Figure 4.4: SDS-PAGE fluorescent gel image showing change in protein 




weight 34 kDA 
mc2 












4.2.2 THL (Tetrahydrolipstatin) strongly inhibits short-chain carboxyl 
esterase activity of BCG_1460c (lipH probable lipase)  
  
Further we found that this short-chain esterase activity of BCG_1460c (lipH 
probable lipase) was inhibited by THL (tetrahydrolipstatin) as indicated by 
IC50 value of 0.12±0.035µM (fig.3.11) while E600 (diethylparanitrophenyl 
phosphate) inhibitor having an IC50 value of 0.399±0.172µM (fig.3.11). These 
values are expected to be even lower for purified enzyme since we performed 
Figure 4.5: Enzymatic assay with whole cell lysate of M. smegmatis  
MC2 over expressing lipH (BCG_1460c) using substrate Pnp-C4 
para-nitrophenol-butyrate (C4) (** n=2 biological replicates) 
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our enzymatic assays using whole cell lysates. The 3D protein structure model 
supports our biochemical data wherein at the structural level our data suggests 
a near attack conformation of β-lactone ring from the active site serine and a 
favourable nucleophilic attack on the carbonyl carbon of β-lactone ring 
therefore opening the β-lactone ring cycle. 
 
4.2.3 Possible functions of BCG_1460c (lipH probable lipase)  
The mycobacterial lip family comprises of 24 putative esterases/lipases of 
which hormone sensitive lipase (HSL) family is a sub-family. BCG_1460c 
(lipH probable lipase) is a member of hormone sensitive lipase (HSL) family 
in this family Rv3097c (lipY) has been reported previously  in  studies 
conducted by Deb and Mishra groups (Deb. et al., 2006 and Mishra et al., 
2008) that Rv3097c (lipY) hydrolyses long-chain TAGs  releasing long-chain 
fatty acids which are used in the glyoxylate cycle while other HSL member 
enzymes such as BCG_1460c (lipH probable lipase) and it is contemplated 
that these maybe involved in short-chain substrate pathways such as 
regulation, detoxification, signalling or support to the membrane and may 
provide mycobacteria an alternate source of carbon. A non-redundant database 
search from BLAST results shown in (table1) reveals that  BCG_1460c (lipH 
probable lipase) gene although a non-essential gene, is found to be 
significantly well conserved right from non-pathogenic soil mycobacteria to 
human pathogenic Mycobacterium tuberculosis as shown in table and 




Table 4.1 BCG_1460c (lipH) homologs in bacterial species  
lipH homologs (BLAST non-redundant database search) 
 
Organism  Gene name  Coverage Identity 
Mycobacterium 
tuberculosis SUMu001  lipase lipH 100% 100% 
Mycobacterium bovis 
BCG str. Pasteur 1173P2, 
Mycobacterium bovis 
BCG str. Tokyo 172, 
Mycobacterium bovis 
BCG str. Mexico, 
Mycobacterium bovis 

















tuberculosis KZN 1435, 
Mycobacterium 
tuberculosis CPHL_A, 
Mtb K85 ,Mtb.  T85, Mtb. 
210, Mtb KZN 4207, Mtb. 











marinum  lipase lipH 99% 79% 
Mycobacterium 
ulcerans Agy99 lipH gene product 99% 79% 
uncultured organism hypothetical 




parascrofulaceum lipase lipH        99%        79% 
Mycobacterium 
tuberculosis '98-R604 




LIPH 98% 76% 
Mycobacterium 
rhodesiae NBB3 esterase/lipase 97% 65% 
Mycobacterium 




lipase 93% 67% 
Mycobacterium 
canettii CIPT 140010059 
putative lipase 








lipase/esterase ,   
lipase lipH 97% 63% 
Mycobacterium 
thermoresistibile ATCC 
19527 esterase 97% 64% 
Mycobacterium 
gilvum Spyr1 esterase/lipase 96% 63% 
Mycobacterium 
smegmatis str. MC2 155 esterase 97% 62% 
Mycobacterium 






       97% 
 
       63% 




intracellulare MOTT-64 lipase LipI 97% 61% 
Mycobacterium 
marinum M lipase LipI 97% 58% 
Mycobacterium 
ulcerans Agy99 lipase LipI 97% 58% 
Mycobacterium sp. 
MCS α/β hydrolase 97% 62% 
Segniliparus rugosus 
ATCC BAA-974] α/β hydrolase 93% 57% 
 
 
The data pertaining to cloning of BCG_1460c (lipH probable lipase), 
BCG_2991c (lipN probable lipase/esterase), BCG_2950 (tesA probable 
thioesterase) and BCG_3229 (lipV possible lipase) were derived from the 
doctoral thesis work of Mr. Ravindran in Prof. Wenk’s lab. The molecular 
modelling and biochemical assay data (figures) for BCG_1460c (lipH 









5. Conclusions and Future directions: 
The present study was undertaken with pointed objectives as enumerated right 
in the beginning. Both In silico as well as In vitro experimental approach were 
adopted to demonstrate the convergence and correlation of the results. The 
outcome provided for the evidence at structural and biochemical level that the 
short-chain esterase activity of BCG_1460c (lipH) was inhibited by 
tetrahydrolipstatin (THL). As pointed out in silico and in vitro analysis 
correlate and the data so obtained provided an effective approach to 
characterize and distinguish lipolytic/non-lipolytic enzymes. To summarize 
the conclusive findings of the present study following points need to be 
emphasized: 
  
 In the present study, it has emerged that the 3D structure models of 4 
mycobcaterial putative esterases/lipases namely BCG_1460c (lipH probable 
lipase), BCG_2991c (lipN probable lipase/esterase), BCG_2950 (tesA 
probable thioesterase) and BCG_3229 (lipV possible lipase) were well 
validated achieving the degree of accuracy to the tune of >95%. In addition 
complete domain modelling of all structures and their respective ligand 
specificities was also undertaken. It is to be pointed out that this was a unique 
feature particularly in view of the fact that only a partial modelling of lipH 
(Rv1399c) and tesA (Rv2928c) was so far done in the studies reported by 
(Canaan et. al.2004) and (Chavadi et. al. 2006) respectively. Further for the 
first time this study validated models for BCG_3229 (lipV possible lipase) and 
BCG_2991c (lipN probable lipase/esterase) 3D structures. 
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 In order to experimentally characterize these and also validate the in 
silico ligand specificity predictions an in vitro biochemical characterization 
was carried out with whole cell lysates of BCG overexpressing BCG_1460c 
(lipH probable lipase), BCG_2991c (lipN probable lipase/esterase), 
BCG_2950 (tesA probable thioesterase) and BCG_3229 (lipV possible lipase). 
Out of these four, one BCG_1460c (lipH probable lipase) was shown to have a 
short chain esterase activity and further inhibitor studies indicated that this 
short chain esterase activity was strongly inhibited by a well-known FDA 
approved drug called THL (Tetrahydrolipstatin).  
 
 In silico molecular modelling predictions put forth were observed to be 
in line with biochemical experimental data making it an effective and 
validated characterization approach to mycobacterial esterases/lipases. 
 
 Future work in continuation to the present work would preferably be to 
understand the exact functional role of BCG_1460c (lipH probable lipase) and 
the pathways in which this enzyme acts in mycobacteria so as to understand its 
exact functional role. At this point of time we can only hypothesize its 
probable function in mycobacteria that it might be acting on short-chain 
substrate pathways such as regulation, detoxification, signalling or support to 
the membrane and may provide mycobacteria an alternate source of carbon. 
However, it would be worthwhile to design and undertake a systematic study 






Ali, Y. B., R. Verger and A. Abousalham (2012). "Lipases or esterases: does it 
really matter? Toward a new bio-physico-chemical classification." Methods 
Mol Biol 861: 31-51. 
 
Canaan, S., D. Maurin, H. Chahinian, B. Pouilly, C. Durousseau, F. 
Frassinetti, L. Scappuccini-Calvo, C. Cambillau and Y. Bourne (2004). 
"Expression and characterization of the protein Rv1399c from Mycobacterium 
tuberculosis. A novel (lipH probable lipase) carboxyl esterase structurally 
related to the HSL family." Eur J Biochem 271(19): 3953-3961. 
 
Daniel, J., C. Deb, V. S. Dubey, T. D. Sirakova, B. Abomoelak, H. R. 
Morbidoni and P. E. Kolattukudy (2004). "Induction of a novel class of 
diacylglycerol acyltransferases and triacylglycerol accumulation in     
Mycobacterium tuberculosis as it goes into a dormancy-like state in culture." J 
Bacteriol 186(15): 5017-5030. 
 
Daniel, J., H. Maamar, C. Deb, T. D. Sirakova and P. E. Kolattukudy (2011). 
"Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid 
droplets and acquires a dormancy-like phenotype in lipid-loaded 
macrophages." PLoS Pathog 7(6): e1002093. 
 
Deb, C., J. Daniel, T. D. Sirakova, B. Abomoelak, V. S. Dubey and P. E. 
Kolattukudy (2006). "A novel lipase belonging to the hormone-sensitive lipase 
family induced under starvation to utilize stored triacylglycerol in 
Mycobacterium tuberculosis." J Biol Chem 281(7): 3866-3875. 
 
Dhouib, R., A. Ducret, P. Hubert, F. Carriere, S. Dukan and S. Canaan (2011). 
"Watching intracellular lipolysis in mycobacteria using time lapse 
fluorescence microscopy." Biochim Biophys Acta 1811(4): 234-241. 
 
Garton, N. J., H. Christensen, D. E. Minnikin, R. A. Adegbola and M. R. 
Barer (2002). "Intracellular lipophilic inclusions of mycobacteria in vitro and 
in sputum." Microbiology 148(Pt 10): 2951-2958. 
 
Kremer, L., C. de Chastellier, G. Dobson, K. J. Gibson, P. Bifani, S. Balor, J. 
P. Gorvel, C. Locht, D. E. Minnikin and G. S. Besra (2005). "Identification 
and structural characterization of an unusual mycobacterial 
monomeromycolyl-diacylglycerol." Mol Microbiol 57(4): 1113-1126. 
 
Lonon, M. K., D. E. Woods and D. C. Straus (1988). "Production of lipase by 
clinical isolates of Pseudomonas cepacia." J Clin Microbiol 26(5): 979-984. 
 
Low, K. L., P. S. Rao, G. Shui, A. K. Bendt, K. Pethe, T. Dick and M. R. 
Wenk (2009). "Triacylglycerol utilization is required for regrowth of in vitro 
hypoxic nonreplicating Mycobacterium bovis bacillus Calmette-Guerin." J 




Low, K. L., G. Shui, K. Natter, W. K. Yeo, S. D. Kohlwein, T. Dick, S. P. Rao 
and M. R. Wenk (2010). "Lipid droplet-associated proteins are involved in the 
biosynthesis and hydrolysis of triacylglycerol in Mycobacterium bovis bacillus 
Calmette-Guerin." J Biol Chem 285(28): 21662-21670. 
 
Mattos, K. A., H. D'Avila, L. S. Rodrigues, V. G. Oliveira, E. N. Sarno, G. C. 
Atella, G. M. Pereira, P. T. Bozza and M. C. Pessolani (2010). "Lipid droplet 
formation in leprosy: Toll-like receptor-regulated organelles involved in 
eicosanoid formation and Mycobacterium leprae pathogenesis." J Leukoc Biol 
87(3): 371-384. 
 
Mattos, K. A., F. A. Lara, V. G. Oliveira, L. S. Rodrigues, H. D'Avila, R. C. 
Melo, P. P. Manso, E. N. Sarno, P. T. Bozza and M. C. Pessolani (2011). 
"Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: a 
putative mechanism for host lipid acquisition and bacterial survival in 
phagosomes." Cell Microbiol 13(2): 259-273. 
 
McKinney, J. D., K. Honer zu Bentrup, E. J. Munoz-Elias, A. Miczak, B. 
Chen, W. T. Chan, D. Swenson, J. C. Sacchettini, W. R. Jacobs, Jr. and D. G. 
Russell (2000). "Persistence of Mycobacterium tuberculosis in macrophages 
and mice requires the glyoxylate shunt enzyme isocitrate lyase." Nature 
406(6797): 735-738. 
 
Parrish, N. M., J. D. Dick and W. R. Bishai (1998). "Mechanisms of latency in 
Mycobacterium tuberculosis." Trends Microbiol 6(3): 107-112. 
 
Peyron, P., J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. 
Daffe, J. F. Emile, B. Marchou, P. J. Cardona, C. de Chastellier and F. Altare 
(2008). "Foamy macrophages from tuberculous patients' granulomas constitute 
a nutrient-rich reservoir for M. tuberculosis persistence." PLoS Pathog 4(11): 
e1000204. 
 
Rollof, J., J. H. Braconier, C. Soderstrom and P. Nilsson-Ehle (1988). 
"Interference of Staphylococcus aureus lipase with human granulocyte 
function." Eur J Clin Microbiol Infect Dis 7(4): 505-510. 
 
Russell, D. G. (2007). "Who puts the tubercle in tuberculosis?" Nat Rev 
Microbiol 5(1): 39-47. 
 
Schue, M., D. Maurin, R. Dhouib, J. C. Bakala N'Goma, V. Delorme, G. 
Lambeau, F. Carriere and S. Canaan (2010). "Two cutinase-like proteins 
secreted by Mycobacterium tuberculosis show very different lipolytic 
activities reflecting their physiological function." FASEB J 24(6): 1893-1903. 
 
Shen, G., K. Singh, D. Chandra, C. Serveau-Avesque, D. Maurin, S. Canaan, 
R. Singla, D. Behera and S. Laal (2012). "LipC (Rv0220) is an immunogenic 




Singh, G., G. Singh, D. Jadeja and J. Kaur (2010). "Lipid hydrolizing enzymes 
in virulence: Mycobacterium tuberculosis as a model system." Crit Rev 
Microbiol 36(3): 259-269. 
 
Wheeler, P. R. and C. Ratledge (1988). "Use of carbon sources for lipid 
biosynthesis in Mycobacterium leprae: a comparison with other pathogenic 
mycobacteria." J Gen Microbiol 134(8): 2111-2121. 
Ali, Y. B., R. Verger and A. Abousalham (2012). "Lipases or esterases: does it 
really matter? Toward a new bio-physico-chemical classification." Methods 
Mol Biol 861: 31-51. 
 
Anuchin, A. M., A. L. Mulyukin, N. E. Suzina, V. I. Duda, G. I. El-Registan 
and A. S. Kaprelyants (2009). "Dormant forms of Mycobacterium smegmatis 
with distinct morphology." Microbiology 155(Pt 4): 1071-1079. 
Beisel, W. R. and R. H. Fiser, Jr. (1970). "Lipid metabolism during infectious 
illness." Am J Clin Nutr 23(8): 1069-1079. 
 
Berto, P., P. Commenil, L. Belingheri and B. Dehorter (1999). "Occurrence of 
a lipase in spores of Alternaria brassicicola with a crucial role in the infection 
of cauliflower leaves." FEMS Microbiol Lett 180(2): 183-189. 
 
Betts, J. C., P. T. Lukey, L. C. Robb, R. A. McAdam and K. Duncan (2002). 
"Evaluation of a nutrient starvation model of Mycobacterium tuberculosis 
persistence by gene and protein expression profiling." Mol Microbiol 43(3): 
717-731. 
 
Camacho, L. R., D. Ensergueix, E. Perez, B. Gicquel and C. Guilhot (1999). 
"Identification of a virulence gene cluster of Mycobacterium tuberculosis by 
signature-tagged transposon mutagenesis." Mol Microbiol 34(2): 257-267. 
 
Camus, J. C., M. J. Pryor, C. Medigue and S. T. Cole (2002). "Re-annotation 
of the genome sequence of Mycobacterium tuberculosis H37Rv." 
Microbiology 148(Pt 10): 2967-2973. 
 
Canaan, S., D. Maurin, H. Chahinian, B. Pouilly, C. Durousseau, F. 
Frassinetti, L. Scappuccini-Calvo, C. Cambillau and Y. Bourne (2004). 
"Expression and characterization of the protein Rv1399c from Mycobacterium 
tuberculosis. A novel carboxyl esterase structurally related to the HSL 
family." Eur J Biochem 271(19): 3953-3961. 
 
Chavadi, S. S., U. R. Edupuganti, O. Vergnolle, I. Fatima, S. M. Singh, C. E. 
Soll and L. E. N. Quadri (2011). "Inactivation of tesA Reduces Cell Wall 
Lipid Production and Increases Drug Susceptibility in Mycobacteria." Journal 
of Biological Chemistry 286(28): 24616-24625. 
 
Chopra, I. (2013). "The 2012 Garrod Lecture: Discovery of antibacterial drugs 




Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. 
Gordon, K. Eiglmeier, S. Gas, C. E. Barry, 3rd, F. Tekaia, K. Badcock, D. 
Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. 
Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, 
J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. 
Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. 
Squares, J. E. Sulston, K. Taylor, S. Whitehead and B. G. Barrell (1998). 
"Deciphering the biology of Mycobacterium tuberculosis from the complete 
genome sequence." Nature 393(6685): 537-544. 
 
Cotes, K., C. Bakala N'goma J, R. Dhouib, I. Douchet, D. Maurin, F. Carriere 
and S. Canaan (2008). "Lipolytic enzymes in Mycobacterium tuberculosis." 
Appl Microbiol Biotechnol 78(5): 741-749. 
 
Cudrey, C., H. van Tilbeurgh, Y. Gargouri and R. Verger (1993). "Inactivation 
of pancreatic lipases by amphiphilic reagents 5-(dodecyldithio)-2-nitrobenzoic 
acid and tetrahydrolipstatin. Dependence upon partitioning between micellar 
and oil phases." Biochemistry 32(50): 13800-13808. 
 
Daniel, J., C. Deb, V. S. Dubey, T. D. Sirakova, B. Abomoelak, H. R. 
Morbidoni and P. E. Kolattukudy (2004). "Induction of a novel class of 
diacylglycerol acyltransferases and triacylglycerol accumulation in 
Mycobacterium tuberculosis as it goes into a dormancy-like state in culture." J 
Bacteriol 186(15): 5017-5030. 
 
Daniel, J., H. Maamar, C. Deb, T. D. Sirakova and P. E. Kolattukudy (2011). 
"Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid 
droplets and acquires a dormancy-like phenotype in lipid-loaded 
macrophages." PLoS Pathog 7(6): e1002093. 
 
Deb, C., J. Daniel, T. D. Sirakova, B. Abomoelak, V. S. Dubey and P. E. 
Kolattukudy (2006). "A novel lipase belonging to the hormone-sensitive lipase 
family induced under starvation to utilize stored triacylglycerol in 
Mycobacterium tuberculosis." J Biol Chem 281(7): 3866-3875. 
 
Dhouib, R., A. Ducret, P. Hubert, F. Carriere, S. Dukan and S. Canaan (2011). 
"Watching intracellular lipolysis in mycobacteria using time lapse 
fluorescence microscopy." Biochim Biophys Acta 1811(4): 234-241. 
 
Dundas, J., Z. Ouyang, J. Tseng, A. Binkowski, Y. Turpaz and J. Liang 
(2006). "CASTp: computed atlas of surface topography of proteins with 
structural and topographical mapping of functionally annotated residues." 
Nucleic Acids Res 34(Web Server issue): W116-118. 
 
Fisher, M. A., B. B. Plikaytis and T. M. Shinnick (2002). "Microarray analysis 
of the Mycobacterium tuberculosis transcriptional response to the acidic 




Garton, N. J., H. Christensen, D. E. Minnikin, R. A. Adegbola and M. R. 
Barer (2002). "Intracellular lipophilic inclusions of mycobacteria in vitro and 
in sputum." Microbiology 148(Pt 10): 2951-2958. 
 
Gu, S., J. Chen, K. M. Dobos, E. M. Bradbury, J. T. Belisle and X. Chen 
(2003). "Comprehensive proteomic profiling of the membrane constituents of 
a Mycobacterium tuberculosis strain." Mol Cell Proteomics 2(12): 1284-1296. 
 
Guex, N. and M. C. Peitsch (1997). "SWISS-MODEL and the Swiss-Pdb 
Viewer: An environment for comparative protein modeling." 
ELECTROPHORESIS 18(15): 2714-2723. 
 
Hadvary, P., H. Lengsfeld and H. Wolfer (1988). "Inhibition of pancreatic 
lipase in vitro by the covalent inhibitor tetrahydrolipstatin." Biochem J 256(2): 
357-361. 
 
Hess, B. (2007). "P-LINCS: A Parallel Linear Constraint Solver for Molecular 
Simulation." Journal of Chemical Theory and Computation 4(1): 116-122. 
 
Hess, B., H. Bekker, H. J. C. Berendsen and J. G. E. M. Fraaije (1997). 
"LINCS: A linear constraint solver for molecular simulations." Journal of 
Computational Chemistry 18(12): 1463-1472. 
 
Hochuli, E., E. Kupfer, R. Maurer, W. Meister, Y. Mercadal and K. Schmidt 
(1987). "Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces 
toxytricini. II. Chemistry and structure elucidation." J Antibiot (Tokyo) 40(8): 
1086-1091. 
 
Hotelier, T., L. Renault, X. Cousin, V. Negre, P. Marchot and A. Chatonnet 
(2004). "ESTHER, the database of the alpha/beta-hydrolase fold superfamily 
of proteins." Nucleic Acids Res 32(Database issue): D145-147. 
 
Jacob, R. B., T. Andersen and O. M. McDougal (2012). "Accessible High-
Throughput Virtual Screening Molecular Docking Software for Students and 
Educators." PLoS Comput Biol 8(5): e1002499. 
 
Kremer, L., C. de Chastellier, G. Dobson, K. J. Gibson, P. Bifani, S. Balor, J. 
P. Gorvel, C. Locht, D. E. Minnikin and G. S. Besra (2005). "Identification 
and structural characterization of an unusual mycobacterial 
monomeromycolyl-diacylglycerol." Mol Microbiol 57(4): 1113-1126. 
 
Larkin, M. A., G. Blackshields, N. P. Brown, R. Chenna, P. A. McGettigan, 
H. McWilliam, F. Valentin, I. M. Wallace, A. Wilm, R. Lopez, J.                 D. 
Thompson, T. J. Gibson and D. G. Higgins (2007). "Clustal W and Clustal X 
version 2.0." Bioinformatics 23(21): 2947-2948. 
 
Lonon, M. K., D. E. Woods and D. C. Straus (1988). "Production of lipase by 




Low, K. L., P. S. Rao, G. Shui, A. K. Bendt, K. Pethe, T. Dick and M. R. 
Wenk (2009). "Triacylglycerol utilization is required for regrowth of in vitro 
hypoxic nonreplicating Mycobacterium bovis bacillus Calmette-Guerin." J 
Bacteriol 191(16): 5037-5043. 
 
Low, K. L., G. Shui, K. Natter, W. K. Yeo, S. D. Kohlwein, T. Dick, S. P. Rao 
and M. R. Wenk (2010). "Lipid droplet-associated proteins are involved in the 
biosynthesis and hydrolysis of triacylglycerol in Mycobacterium bovis bacillus 
Calmette-Guerin." J Biol Chem 285(28): 21662-21670. 
 
Mattos, K. A., H. D'Avila, L. S. Rodrigues, V. G. Oliveira, E. N. Sarno, G. C. 
Atella, G. M. Pereira, P. T. Bozza and M. C. Pessolani (2010). "Lipid droplet 
formation in leprosy: Toll-like receptor-regulated organelles involved in 
eicosanoid formation and Mycobacterium leprae pathogenesis." J Leukoc Biol 
87(3): 371-384. 
 
Mattos, K. A., F. A. Lara, V. G. Oliveira, L. S. Rodrigues, H. D'Avila, R. C. 
Melo, P. P. Manso, E. N. Sarno, P. T. Bozza and M. C. Pessolani (2011). 
"Modulation of lipid droplets by Mycobacterium leprae in Schwann cells: a 
putative mechanism for host lipid acquisition and bacterial survival in 
phagosomes." Cell Microbiol 13(2): 259-273. 
 
McKinney, J. D., K. Honer zu Bentrup, E. J. Munoz-Elias, A. Miczak, B. 
Chen, W. T. Chan, D. Swenson, J. C. Sacchettini, W. R. Jacobs, Jr. and D. G. 
Russell (2000). "Persistence of Mycobacterium tuberculosis in macrophages 
and mice requires the glyoxylate shunt enzyme isocitrate lyase." Nature 
406(6797): 735-738. 
 
Menendez, J. A., L. Vellon and R. Lupu (2005). "Antitumoral actions of the 
anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell 
cycle progression, promotion of apoptotic cell death and PEA3-mediated 
transcriptional repression of Her2/neu (erbB-2) oncogene." Ann Oncol 16(8): 
1253-1267. 
 
Mishra, K. C., C. de Chastellier, Y. Narayana, P. Bifani, A. K. Brown, G. S. 
Besra, V. M. Katoch, B. Joshi, K. N. Balaji and L. Kremer (2008). "Functional 
role of the PE domain and immunogenicity of the Mycobacterium tuberculosis 
triacylglycerol hydrolase LipY." Infect Immun 76(1): 127-140. 
 
Morris, G. M., D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. 
Belew and A. J. Olson (1998). "Automated docking using a Lamarckian 
genetic algorithm and an empirical binding free energy function." Journal of 
Computational Chemistry 19(14): 1639-1662. 
 
O'Reilly, L. M. and C. J. Daborn (1995). "The epidemiology of 
Mycobacterium bovis infections in animals and man: a review." Tuber Lung 




Ollis, D. L., E. Cheah, M. Cygler, B. Dijkstra, F. Frolow, S. M. Franken, M. 
Harel, S. J. Remington, I. Silman, J. Schrag and et al. (1992). "The alpha/beta 
hydrolase fold." Protein Eng 5(3): 197-211. 
 
Parrish, N. M., J. D. Dick and W. R. Bishai (1998). "Mechanisms of latency in 
Mycobacterium tuberculosis." Trends Microbiol 6(3): 107-112. 
 
Peyron, P., J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. 
Daffe, J. F. Emile, B. Marchou, P. J. Cardona, C. de Chastellier and F. Altare 
(2008). "Foamy macrophages from tuberculous patients' granulomas constitute 
a nutrient-rich reservoir for M. tuberculosis persistence." PLoS Pathog 4(11): 
e1000204. 
 
Polgar, T. (2007). "[The role of structure based virtual screening in the early 
phase of drug discovery]." Acta Pharm Hung 77(4): 223-234. 
 
Richter, L. and B. Saviola (2009). "The lipF promoter of Mycobacterium 
tuberculosis is upregulated specifically by acidic pH but not by other stress 
conditions." Microbiol Res 164(2): 228-232. 
 
Rollof, J., J. H. Braconier, C. Soderstrom and P. Nilsson-Ehle (1988). 
"Interference of Staphylococcus aureus lipase with human granulocyte 
function." Eur J Clin Microbiol Infect Dis 7(4): 505-510. 
 
Russell, D. G. (2007). "Who puts the tubercle in tuberculosis?" Nat Rev 
Microbiol 5(1): 39-47. 
 
Schue, M., D. Maurin, R. Dhouib, J. C. Bakala N'Goma, V. Delorme, G. 
Lambeau, F. Carriere and S. Canaan (2010). "Two cutinase-like proteins 
secreted by Mycobacterium tuberculosis show very different lipolytic 
activities reflecting their physiological function." FASEB J 24(6): 1893-1903. 
 
Shen, G., K. Singh, D. Chandra, C. Serveau-Avesque, D. Maurin, S. Canaan, 
R. Singla, D. Behera and S. Laal (2012). "LipC (Rv0220) is an immunogenic 
cell surface esterase of Mycobacterium tuberculosis." Infect Immun 80(1): 
243-253. 
Simmons, K. J., I. Chopra and C. W. G. Fishwick (2010). "Structure-based 
discovery of antibacterial drugs." Nat Rev Micro 8(7): 501-510. 
 
Singh, G., G. Singh, D. Jadeja and J. Kaur (2010). "Lipid hydrolizing enzymes 
in virulence: Mycobacterium tuberculosis as a model system." Crit Rev 
Microbiol 36(3): 259-269. 
 
Suplatov, D. A., W. Besenmatter, V. K. Svedas and A. Svendsen (2012). 
"Bioinformatic analysis of alpha/beta-hydrolase fold enzymes reveals 
subfamily-specific positions responsible for discrimination of amidase and 




Thomson, C. A., P. J. Delaquis and G. Mazza (1999). "Detection and 
measurement of microbial lipase activity: a review." Crit Rev Food Sci Nutr 
39(2): 165-187. 
 
Tortoli, E. (2006). "The new mycobacteria: an update." FEMS Immunol Med 
Microbiol 48(2): 159-178. 
 
Trott, O. and A. J. Olson (2010). "AutoDock Vina: Improving the speed and 
accuracy of docking with a new scoring function, efficient optimization, and 
multithreading." Journal of Computational Chemistry 31(2): 455-461. 
 
van Beers, S. M., M. Y. de Wit and P. R. Klatser (1996). "The epidemiology 
of Mycobacterium leprae: recent insight." FEMS Microbiol Lett 136(3): 221-
230. 
 
Wheeler, P. R. and C. Ratledge (1988). "Use of carbon sources for lipid 
biosynthesis in Mycobacterium leprae: a comparison with other pathogenic 
mycobacteria." J Gen Microbiol 134(8): 2111-2121. 
 
Wiederstein, M. and M. J. Sippl (2007). "ProSA-web: interactive web service 
for the recognition of errors in three-dimensional structures of proteins." 
Nucleic Acids Res 35(Web Server issue): W407-410. 
 
Xu, G., H. Jia, Y. Li, X. Liu, M. Li and Y. Wang (2010). "Hemolytic 
phospholipase Rv0183 of Mycobacterium tuberculosis induces inflammatory 
response and apoptosis in alveolar macrophage RAW264.7 cells." Can J 
Microbiol 56(11): 916-924. 
 
Zhang, J., Y. Liang and Y. Zhang (2011). "Atomic-Level Protein Structure 
Refinement Using Fragment-Guided Molecular Dynamics Conformation 
Sampling." Structure (London, England : 1993) 19(12): 1784-1795. 
 
Zhang, M., J. D. Wang, Z. F. Li, J. Xie, Y. P. Yang, Y. Zhong and H. H. 
Wang (2005). "Expression and characterization of the carboxyl esterase 
Rv3487c from Mycobacterium tuberculosis." Protein Expr Purif 42(1): 59-66. 
 
Solis, F. J., and Wets, R. J.-B. (1981) “Minimization by Random Search 
Techniques,” Mathematics of Operations Research, 6, 19-30. 
 
Sun Hur andThomas C. Bruice  (2003) “The near attack conformation 
approach to the study of the chorismate to prephenate reaction”, 
PNAS 2003 100  
 
 
 
 87 
 
 
 
 
 
 
